

Please type a plus sign (+) inside this box → +

# COPY

1FW

Substitute for form 1449A/B/PTO


## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 33

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/588,323       |
| Filing Date            | February 7, 2005 |
| First Named Inventor   | MAGILAVY         |
| Group Art Unit         | 1644             |
| Examiner Name          | Unassigned       |
| Attorney Docket Number | 253780           |



### U.S. PATENT DOCUMENTS


| Initials | Doc. No. | U.S. Patent Document         |           | Name of Patentee or Applicant | Date of Publication | Filing Date If Appropriate |
|----------|----------|------------------------------|-----------|-------------------------------|---------------------|----------------------------|
|          |          | Application or Patent Number | Kind Code |                               |                     |                            |
|          | A1       | 2003/0044406                 | A1        | Dingivan                      | 03/06/2003          |                            |
|          | A2       | 2003/0185824                 | A1        | Vaishnow et al.               | 10/02/2003          |                            |
|          | A3       | 2002/0009446                 | A1        | Magilavy                      | 01/24/2002          |                            |
|          | A4       | 4,579,844                    |           | Rovee et al.                  | 04/01/1986          |                            |
|          | A5       | 4,681,760                    |           | Fathman                       | 07/21/1987          |                            |
|          | A6       | 4,738,297                    |           | Taniguchi et al.              | 04/19/1988          |                            |
|          | A7       | 4,738,927                    |           | Taniguchi et al.              | 04/19/1988          |                            |
|          | A8       | 4,816,397                    |           | Boss et al.                   | 03/28/1989          |                            |
|          | A9       | 4,816,567                    |           | Cabilly et al.                | 03/28/1989          |                            |
|          | A10      | 4,833,092                    |           | Geysen                        | 05/23/1989          |                            |
|          | A11      | 4,956,281                    |           | Wallner et al.                | 09/11/1990          |                            |
|          | A12      | 5,047,336                    |           | Cate et al.                   | 09/10/1991          |                            |
|          | A13      | 5,116,964                    |           | Capon et al.                  | 05/26/1992          |                            |
|          | A14      | 5,122,514                    |           | Boger et al.                  | 06/16/1992          |                            |
|          | A15      | 5,185,441                    |           | Wallner et al.                | 02/09/1993          |                            |
|          | A16      | 5,190,859                    |           | Dustin et al.                 | 03/02/1993          |                            |
|          | A17      | 5,225,538                    |           | Capon et al.                  | 07/06/1993          |                            |
|          | A18      | 5,336,603                    |           | Capon et al.                  | 09/09/1994          |                            |
|          | A19      | 5,547,853                    |           | Wallner et al.                | 08/20/1996          |                            |
|          | A20      | 5,556,943                    |           | Yamashita et al.              | 09/17/1996          |                            |
|          | A21      | 5,565,335                    |           | Capon et al.                  | 10/15/1996          |                            |
|          | A22      | 5,728,677                    |           | Wallner et al.                | 03/17/1998          |                            |
|          | A23      | 5,730,979                    |           | Bazin et al.                  | 03/24/1998          |                            |
|          | A24      | 5,817,311                    |           | Bazin et al.                  | 10/06/1998          |                            |
|          | A25      | 5,914,111                    |           | Wallner et al.                | 06/22/1999          |                            |
|          | A26      | 5,928,643                    |           | Wallner et al.                | 07/27/1999          |                            |
|          | A27      | 5,951,983                    |           | Bazin et al.                  | 09/14/1999          |                            |
|          | A28      | 5,952,499                    |           | Whittaker et al.              | 09/14/1999          |                            |
|          | A29      | 6,117,655                    |           | Capon et al.                  | 09/12/2000          |                            |
|          | A30      | 6,162,432                    |           | Wallner et al.                | 12/19/2000          |                            |
|          | A31      | 6,270,766                    |           | Feldman et al.                | 08/07/2001          |                            |
|          | A32      | 6,337,337                    | B1        | Buck                          | 01/08/2002          |                            |
|          | A33      | 6,384,198                    | B1        | Diegel et al.                 | 05/07/2002          |                            |
|          | A34      | 6,764,681                    | B2        | Wallner et al.                | 07/20/2004          |                            |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials  | Doc. No. | Foreign Patent Document |                              |           | Name of Patentee or Applicant      | Date of Publication | Translation |       |
|--------------------|----------|-------------------------|------------------------------|-----------|------------------------------------|---------------------|-------------|-------|
|                    |          | Office                  | Application or Patent Number | Kind Code |                                    |                     | Yes         | No* + |
|                    | B1       | CA                      | 1,326,940                    |           | Dana-Farber Cancer Institute, Inc. | Feb. 08, 1994       |             |       |
| Examiner Signature |          |                         |                              |           | Date Considered                    |                     |             |       |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 


|   |            |    |    |                          |                  |
|---|------------|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |            |    |    | <b>Complete if Known</b> |                  |
|   |            |    |    | Application Number       | 10/588,323       |
|   |            |    |    | Filing Date              | February 7, 2005 |
|   |            |    |    | First Named Inventor     | MAGILAVY         |
|   |            |    |    | Group Art Unit           | 1644             |
| Examiner Name   | Unassigned |    |    |                          |                  |
| Sheet   | 2          | of | 33 | Attorney Docket Number   | 253780           |

| FOREIGN PATENT DOCUMENTS |          |                         |                              |           |  |                     |             |          |
|--------------------------|----------|-------------------------|------------------------------|-----------|--|---------------------|-------------|----------|
| Examiner Initials        | Doc. No. | Foreign Patent Document |                              |           | Name of Patentee or Applicant  | Date of Publication | Translation |          |
|                          |          | Office                  | Application or Patent Number | Kind Code |  |                     | Yes         | No*<br>+ |
|                          | B2       | CA                      | 1,338,078                    |           | Michael, Jacob Gabriel   | Feb. 20, 1996       |             |          |
|                          | B3       | CA                      | 2,120,500                    |           | The General Hospital Corporation   | Apr. 15, 1993       |             |          |
|                          | B4       | EP                      | 0 200 412                    | A2        | The Board of Trustees of the Leland Stanford Junior University                             | Dec. 10, 1986       |             |          |
|                          | B5       | EP                      | 0 260 880                    | A2        | Dana-Farber Cancer Institute, Inc.   | Mar. 23, 1988       |             |          |
|                          | B6       | EP                      | 0 280 578                    | A2        | Dana Farber Cancer Institute   | Aug. 31, 1988       |             |          |
|                          | B7       | EP                      | 0 314 317                    | B1        | Genentech, Inc.  | Mar. 5, 1989        |             |          |
|                          | B8       | EP                      | 0 325 262                    | B1        | The General Hospital Corporation   | Mar. 16, 1994       |             |          |
|                          | B9       | EP                      | 0 325 266                    | A2        | ESPE Stiftung & Co Produktions- und Vertriebs KG   | Jul. 26, 1989       |             | X+       |
|                          | B10      | EP                      | 0 345 466                    | A2        | Eastman Kodak Company  | Dec. 13, 1989       |             |          |
|                          | B11      | EP                      | 0 368 684                    | B2        | Medical Research Council   | May. 16, 1990       |             |          |
|                          | B12      | EP                      | 0 503 646                    | A1        | Biogen, Inc.   | Sep. 16, 1992       |             |          |
|                          | B13      | EP                      | 0 503 648                    | A1        | Biogen, Inc.   | Sep. 16, 1992       |             |          |
|                          | B14      | EP                      | 0 517 174                    | B1        | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha  | Dec. 9, 1992        |             |          |
|                          | B15      | EP                      | 0 607 332                    | B1        | Biogen, Inc.   | Dec. 17, 1997       |             |          |
|                          | B16      | EP                      | 0 626 447                    | A1        | Bristol-Myers Squibb Company   | Nov. 30, 1994       |             |          |
|                          | B17      | EP                      | 1 637 155                    | A1        | Biogen Idec MA Inc.  | Mar. 22, 2006       |             |          |
|                          | B18      | JP                      | 1-502875                     | T2        | Medical Research Council   | Oct. 24, 1990       |             |          |
|                          | B19      | JP                      | 2-503269                     | T2        | The Trustees of Columbia University in the City of New York Smithkline Beckman Corporation | Oct. 11, 1990       |             |          |
|                          | B20      | JP                      | 7-502495                     | T2        | Biogen, Inc.   | Mar. 16, 1995       |             | X+       |
|                          | B21      | JP                      | 2-501113                     | T2        | Dana-Farber Cancer Institute, Inc.   | Apr. 19, 1990       |             | X+       |
|                          | B22      | JP                      | 63-233917                    | T2        | Cosmo Kaihatsu KK  | Sep. 29, 1988       |             |          |
|                          | B23      | WO                      | 88/06592                     | A1        | Dana Farber Cancer Institute   | Sep. 7, 1988        |             |          |
|                          | B24      | WO                      | 88/07089                     | A1        | Medical Research Council   | Sep. 22, 1988       |             |          |
|                          | B25      | WO                      | 88/09820                     | A1        | Biogen N.V. et al.   | Dec. 15, 1988       |             |          |
|                          | B26      | WO                      | 89/02922                     | A1        | Genentech, Inc.  | Apr. 6, 1989        |             |          |
|                          | B27      | WO                      | 89/07452                     | A1        | Medical Research Council   | Aug. 24, 1989       |             |          |
|                          | B28      | WO                      | 90/02181                     | A1        | Biogen, Inc.   | Mar. 8, 1990        |             |          |
|                          | B29      | WO                      | 90/07517                     | A1        | The Salk Institute for Biological Studies  | Jul. 12, 1990       |             |          |
|                          | B30      | WO                      | 90/08187                     | A1        | Dana Farber Cancer Institute   | July 26, 1990       |             |          |
|                          | B31      | WO                      | 90/09195                     | A1        | Celltech Limited   | Aug. 23, 1990       |             |          |
|                          | B32      | WO                      | 90/12099                     | A1        | Biogen, Inc.   | Oct. 18, 1990       |             |          |
|                          | B33      | WO                      | 91/07987                     | A1        | Immunomedics, Inc.   | Jun. 13, 1991       |             |          |
|                          | B34      | WO                      | 91/10741                     | A1        | Cell Genesys, Inc.   | Jul. 25, 1991       |             |          |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |            |    |    |                          |                  |
|---|------------|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |            |    |    | <b>Complete if Known</b> |                  |
|   |            |    |    | Application Number       | 10/588,323       |
|   |            |    |    | Filing Date              | February 7, 2005 |
|   |            |    |    | First Named Inventor     | MAGILAVY         |
|   |            |    |    | Group Art Unit           | 1644             |
| Examiner Name   | Unassigned |    |    |                          |                  |
| Sheet   | 3          | of | 33 | Attorney Docket Number   | 253780           |


| FOREIGN PATENT DOCUMENTS |             |                         |                                 |              |  |                     |             |          |
|--------------------------|-------------|-------------------------|---------------------------------|--------------|--|---------------------|-------------|----------|
| Examiner<br>Initials     | Doc.<br>No. | Foreign Patent Document |                                 |              | Name of Patentee or Applicant            | Date of Publication | Translation |          |
|                          |             | Office                  | Application or<br>Patent Number | Kind<br>Code |  |                     | Yes         | No*<br>+ |
|                          | B35         | WO                      | 91/11461                        | A1           | Biogen, Inc.                             | Aug. 8, 1991        |             |          |
|                          | B36         | WO                      | 91/11194                        | A1           | Biogen, Inc.                             | Aug. 8, 1991        |             |          |
|                          | B37         | WO                      | 92/07581                        | A1           | Autoimmune, Inc.                         | May 14, 1992        |             |          |
|                          | B38         | WO                      | 93/06866                        | A2           | Biogen, Inc.                             | Apr. 15, 1993       |             |          |
|                          | B39         | WO                      | 93/06852                        | A2           | Biogen, Inc.                             | Apr. 15, 1993       |             |          |
|                          | B40         | WO                      | 95/24217                        | A1           | Dana-Farber Cancer Institute             | Sep. 14, 1995       |             |          |
|                          | B41         | WO                      | 98/05357                        | A1           | The Kennedy Institute of<br>Rheumatology | Feb. 12, 1998       |             |          |
|                          | B42         | WO                      | 2002/060480                     | A1           | Biogen, Inc.                             | Aug. 8, 2002        |             |          |
|                          | B43         | WO                      | 03/009740                       | A3           | Biogen, Inc.                             | Feb. 6, 2003        |             |          |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |  |  |  |  |             |      |
|---|-------------|--|--|--|--|--|-------------|------|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. |  |  |  |  | Translation |      |
|   |             |  |  |  |  |  | Yes         | No** |
|   | C1          | ABRAHAM et al. (1990) "Interactions between lymphocytes and dermal fibroblasts: An <i>in vitro</i> model of cutaneous lymphocyte trafficking," Experimental Cell Research 190, 118-126   |  |  |  |  |             |      |
|   | C2          | ABRAHAM, et al., (1991) "Expression and Function of Surface Antigens on Scleroderma Fibroblasts" Arthritis and Rheumatism 34(9):1164-1172.   |  |  |  |  |             |      |
|   | C3          | ACTIS, et al., "Continuously Infused Cyclosporine at Low Dose Is Sufficient to Avoid Emergency Colectomy in Acute Attacks of Ulcerative Colitis Without the Need for High-Dose Steroids", Journal of Clinical Gastroenterology, vol. 17, No. 1, pp. 10-13, 1993. |  |  |  |  |             |      |
|   | C4          | ADAMS, "How the Immune System Works and Why it Causes Autoimmune Diseases" Immunology Today, 1996 Jul.;17(7):300-2.  |  |  |  |  |             |      |
|   | C5          | ALBERT-WOLF, et al., "Immunomodulatory Properties of Soluble Recombinant Human CD58 (LFA-3) Molecules", Dev. Biol. Standard 77:87-92 (1992)  |  |  |  |  |             |      |
|   | C6          | ALBERTS et al., Molecular Biology of the Cell, 1994, Garland Publishing, Inc., New York, NY, pp. 1243, 1994.   |  |  |  |  |             |      |
|   | C7          | ALCOVER, et al., "Interdependence of CD3-Ti and CD2 Activation Pathways in Human T Lymphocytes", The EMBO Journal, vol. 7, No. 7, pp. 1973-1977, 1988.   |  |  |  |  |             |      |
|   | C8          | ALORA, et al., "Narrow-band (311 nm) UVB Phototherapy: An Audit of the First Year's experience at the Massachusetts General Hospital", Photodermatology Photoimmunology & Photomedicine, vol. 13, pp. 82-84, 1997.   |  |  |  |  |             |      |
|   | C9          | ALTMAN et al. (1990) "Transfection of genes for cell surface products involved in antigen presentation-applications to the understanding of autoimmunity" Autoimmunity 7:213-220.  |  |  |  |  |             |      |
|   | C10         | ALTMAYER, et al. "Traitement Systemique Du Psoriasis Par Les Derives De L'Acide Fumarique", Ann. Dermatol. Venereol, vol. 123, pp. 838-841, 1996   |  |  |  |  |             |      |
|   | C11         | ALTSHULER, "Implications of Psoriasis as a New Disease", Dermatology, vol. 199, pp. 1-2, 1999.   |  |  |  |  |             |      |
|   | C12         | AMEEN, "Genetic basis of psoriasis vulgaris and its pharmacogenetic potential", Pharmacogenomics 4(3); 297-308 (2003)  |  |  |  |  |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |            |    |    |                          |                  |
|---|------------|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |            |    |    | <b>Complete if Known</b> |                  |
|   |            |    |    | Application Number       | 10/588,323       |
|   |            |    |    | Filing Date              | February 7, 2005 |
|   |            |    |    | First Named Inventor     | MAGILAVY         |
|   |            |    |    | Group Art Unit           | 1644             |
| Examiner Name   | Unassigned |    |    |                          |                  |
| Attorney Docket Number  | 253780     |    |    |                          |                  |
| Sheet   | 4          | of | 33 |                          |                  |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C13         | ARBUCKLE, et al., "Psoriasis" Pediatrics in Review, 1998 Mar.;19(3):106-7.   |             |      |  |
|   | C14         | ARELLANO, "Risk of Cancer with Cyclosporine in Psoriasis" International Journal of Dermatology, vol. 36, No. 1, pp. 15-17, 1997.   |             |      |  |
|   | C15         | AREND, "The Pathophysiology and Treatment of Rheumatoid Arthritis" Arthritis & Rheumatism, vol. 40, No. 4, pp. 595-597, 1997.  |             |      |  |
|   | C16         | ARMITAGE, "Tests for Linear Trends in Proportions and Frequencies" Biometrics, 11, 375-386, 1955.  |             |      |  |
|   | C17         | ARTHOS, et al., "Identification of the Residues in Human CD4 Critical for the Binding of HIV", Cell, 57(3):469-481 (1989)  |             |      |  |
|   | C18         | ASADULLAH, et al., "IL-10 Is a Key Cytokine in Psoriasis", Journal of Clinical Investigation, vol. 101, No. 4, pp. 783-794, 1998.  |             |      |  |
|   | C19         | ASHCROFT, et al., "Clinical Measures of Disease Severity and Outcome in Psoriasis: A Critical Appraisal of their Quality" British Journal of Dermatology, vol. 141, pp. 185-191, 1999.   |             |      |  |
|   | C20         | ATCC Cell Lines and Hybridomas 8th Edition 1994 p. 420 only.   |             |      |  |
|   | C21         | BAADSGAARD et al. (1989) "Psoriatic Epidermal Cells Demonstrate Increased Nos. and Function of Non-Langerhans Antigen-presenting Cells" J. Invest. Dermatol. 92:190-195.   |             |      |  |
|   | C22         | BANGHA et al., "Evaluation of Topical Antipsoriatic Treatment by Chromametry, Visiometry and 20-MHz Ultrasound in the Psoriasis Plaque Test", Skin Pharmacology, vol. 9, pp. 298-306, 1996.  |             |      |  |
|   | C23         | BANSIL, et al. "Multiple Sclerosis: Immune Mechanism and Update on Current Therapies" Annals of Neurology, 37 (S1): 87-101, 1995.  |             |      |  |
|   | C24         | BARBOSA et al. (1986) "Gene Mapping and Somatic Cell Hybrid Analysis Of The Role Of Human Lymphocyte Function-Associated Antigen-3 (LFA-3) in CTL-Target Cell Interactions" J. Immunol. 136 (8):3085-3091.   |             |      |  |
|   | C25         | BARDOLPH et al., "Psoriasis: A Review of Present and Future Manangement", Nursing Standard, vol. 12, No. 21, pp. 43-47, 1998.  |             |      |  |
|   | C26         | BARKER, "Psoriasis" Journal of the Royal College of Physicians of London, vol. 31, No. 3, pp. 238-240, 1997.   |             |      |  |
|   | C27         | BARKER, "The Pathophysiology of Psoriasis", The Lancet, vol. 338, pp. 227-230, 1991.   |             |      |  |
|   | C28         | BARKER, et al., "Leukocyte-Endothelium Interactions in Cutaneous Inflammatory Processes", Springer Seminars in Immunopathology, vol. 13, pp. 355-367, 1992.  |             |      |  |
|   | C29         | BARKER, et al., "Topical Maxacalcitol for the Treatment of Psoriasis Vulgaris: A Placebo-Controlled, Double-Blind, Dose-Finding Study with Active Comparator", British Journal of Dermatology, vol. 141, pp. 274-278, 1999.                                      |             |      |  |
|   | C30         | BARSOUM, "Introduction of Stable High-Copy-Number DNA into Chinese Hamster Ovary Cells by Electroporation" DNA and Cell Biology, vol. 9, No. 4, pp. 293-300, 1990.   |             |      |  |
|   | C31         | BARTHELS et al., "Isolation and Nucleotide Sequence of Mouse NCAM cDNA that Codes for a M.sub.r 79000 Polypeptide Without a Membrane-Spanning Region," EMBO Journal, 6 (4), pp. 907-914 (1987).  |             |      |  |
|   | C32         | BAY, et al., "Psoriasis Patients have T-cells with Reduced Responsiveness to Common Mycobacterial Antigens", FEMS Immunology and Medical Microbiology, vol. 21, pp. 65-70, 1998.   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |   |    |    |                          |                  |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |    | <b>Complete if Known</b> |                  |
|   |   |    |    | Application Number       | 10/588,323       |
|   |   |    |    | Filing Date              | February 7, 2005 |
|   |   |    |    | First Named Inventor     | MAGILAVY         |
|   |   |    |    | Group Art Unit           | 1644             |
|   |   |    |    | Examiner Name            | Unassigned       |
| Sheet   | 5 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |  |             |      |  |
|---|----------|--|-------------|------|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |          |  | Yes         | No** |  |
|   | C33      | BELL, et al, "CD2 and the Regulation of T Cell Anergy", J Immunol. 1995 Sep. 15;155(6):2805-7.   |             |      |  |
|   | C34      | BENJAMIN, et al., "MAb to cell interaction antigens block human T-dependent B cell activation", J. Cell. Biochem. Keystone Symposia on Molecular & Cellular Biology Supp. 17B:172 (1993)   |             |      |  |
|   | C35      | BENNET, "Cyclosporine Nephrotoxicity: Implications for Dermatology", International Journal of Dermatology, vol. 36(Supp. 1), pp. 11-14, 1997.  |             |      |  |
|   | C36      | BENTON et al., "Screening the Recombinant Clones by Hybridization to Single Plaques in situ", Science, 196, 180-182 (1977).  |             |      |  |
|   | C37      | BERTH-JONES, et al., "Treatment of Psoriasis with Intermittent Short Course Cyclosporin (Neoral.RTM.). A Multicentre Study", British Journal of Dermatology, vol. 136, pp. 527-530, 1997.  |             |      |  |
|   | C38      | BIEBER et al. (1981) "Complications in long-term survivors of cardiac transplantation", Transplant Proc. 8(1): 207-211.  |             |      |  |
|   | C39      | BIERER, et al. (1988) "T Cell Adhesion Molecules" FASEB J. 2:2584-2590.  |             |      |  |
|   | C40      | BIERER et al. (1988) "Expression Of The T-Cell Surface Molecule CD2 And An Epitope-Loss CD2 Mutant To Define The Role Of Lymphocyte Function-Associated Antigen 3 (LFA-3) in T-Cell Activation" Proc. Natl. Acad. Sci. USA 85:1194-1198.                         |             |      |  |
|   | C41      | BIERER et al. (1989) "A Monoclonal Antibody to LFA-3, the CD2 Ligand, Specifically Immobilizes Major Histocompatibility Complex Proteins" Eur. J. Immunol. 19:661-665.   |             |      |  |
|   | C42      | BIERER, B. et al. "Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor", J. Exp. Med. 168: 1145-1156, Sep. 1988.   |             |      |  |
|   | C43      | BJERKE, et al., "Acitretin Versus Etretnate in Severe Psoriasis. A double-blind Randomized Nordic Multicenter Study in 168 Patients", Acta Derm Venereol Suppl (Stockh), Vool. 146, pp. 206-207, 1989.   |             |      |  |
|   | C44      | BJERRING, et al., "Topical Treatment of Psoriatic Skin with Methotrexate Cream: A Clinical, Pharmacokinetic, and Histological Study", Acta Derm Venereol (Stockh), vol. 66, pp. 515-519, 1986.   |             |      |  |
|   | C45      | BOCKENSTEDT et al. (1988) "The CD2 Ligand LFA-3 Activates T Cells But Depends On The Expression And Function Of The Antigen Receptor" J. Immunol. 141:1904-1911.   |             |      |  |
|   | C46      | BOEHNCKE, et al., "Differential Expression of Adhesion Molecules on Infiltrating Cells Inflammatory Dermatoses", Journal of American Academy of Dermatology, vol. 26, No. 6, pp. 907-913, 1992.  |             |      |  |
|   | C47      | BONIFATI, et al., "Recognition and Treatment of Psoriasis: Special Considerations in Elderly Patients" Drugs & Aging, vol. 12, No. 3, pp. 177-190, 1998.   |             |      |  |
|   | C48      | BONNERJEA, et al. "Protein Purification: The Right Step at the Right Time" Bio/Technology 4:955 (1986)   |             |      |  |
|   | C49      | BORRONI, et al., "Evidence for CD8+ Cell Increase in Long-Term PUVA-Treated Psoriatic Patients after PUVA Discontinuation", Dermatology, vol. 185, pp. 69-71, 1992.  |             |      |  |
|   | C50      | BOS, et al., "Immunologie in de Medische Praktijk. VII. Psoriasis", Ned Tijdschr Geneesk, vol. 141, No. 48, pp. 2334-2338, 1997.   |             |      |  |
|   | C51      | BOUHNICK, et al., "Long- term Follow-up of Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine", The Lancet, vol. 347, pp. 215-219, 1996.  |             |      |  |
| Examiner Signature                      |          | Date Considered  |             |      |  |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |   |    |    |                          |                  |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |    | <b>Complete if Known</b> |                  |
|   |   |    |    | Application Number       | 10/588,323       |
|   |   |    |    | Filing Date              | February 7, 2005 |
|   |   |    |    | First Named Inventor     | MAGILAVY         |
|   |   |    |    | Group Art Unit           | 1644             |
|   |   |    |    | Examiner Name            | Unassigned       |
| Sheet   | 6 | of | 33 | Attorney Docket Number   | 253780           |

**OTHER - NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|----------------------|-------------|--|-------------|------|
|                      |             |  | Yes         | No** |
|                      | C52         | BOVENSCHEN, et al., "Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis", Arch. Dermatol. Res. 298: 457-463 (2007)   |             |      |
|                      | C53         | BOWIE et al. Deciphering the messages in protein sequences: Tolerance to amini acid substitutions. Science 240:1306-1310, Mar. 1990.   |             |      |
|                      | C54         | BRESSLER, P., et al., "Anti-CD2 Receptor Antibodies Activate the HIV Long Terminal Repeat in T Lymphocytes," J. Immunol., 147(7), pp. 2290-2294 (Oct. 1, 1991).  |             |      |
|                      | C55         | BROD, S. A. et al., "T-T Cell Interactions Are Mediated by Adhesion Molecules," Eur. J. Immunol., 20, pp. 2259-2268 (1990).  |             |      |
|                      | C56         | BROMBERG et al. (1991) "Anti-CD2 Monoclonal Antibodies Alter Cell-Mediated Immunity In Vivo" Transplantation 51:219-225.   |             |      |
|                      | C57         | BROTTIER, et al., "T Cell Activation Via CD2 [T, gp50] Molecules: Accessory Cells are Required to Trigger T Cell Activation via CD2-D66 Plus CD2-9.6/T11.sub.I Epitopes.sup.I ", The Journal of Immunology, vol. 135(3), pp. 1624-1631, 1985.                    |             |      |
|                      | C58         | BROWN et al. (1987) "T2.2 Characterization Of CD2 Epitopes By Western Blotting" in Leukocyte Typing III, A.J. McMichael (ed.) Oxford, England: Oxford University Press, 110-112.   |             |      |
|                      | C59         | BROWN et al. (1989) "The CD2 Antigen Associates With The T-Cell Antigen Receptor CD3 Antigen Complex On The Surface Of Human T Lymphocytes" Nature 339: 551-553.   |             |      |
|                      | C60         | BUCHERRI, et al., "Acitretin Therapy is Effective for Psoriasis Associated with Human Immunodeficiency Virus Infection", Archives of Dermatology, vol. 133, pp. 711-715, 1997.   |             |      |
|                      | C61         | BURDEN, "Management of Psoriasis in Childhood", Clinical and Experimental Dermatology, vol. 24, pp. 341-345;1999.  |             |      |
|                      | C62         | BURNS, et al., "Intralesional Cyclosporine for Psoriasis", Archives of Dermatology, vol. 128, pp. 786-790, 1992.   |             |      |
|                      | C63         | CAMISA, Psoriasis , Blackwell Scientific Publications, 1994, 1.sup.st Ed.  |             |      |
|                      | C64         | CAPON, et al., "Designing CD4 immunoadhesins for AIDS therapy", Nature 337(9): 525-531(1989)   |             |      |
|                      | C65         | CARRERA, et al. "Triggering of co-mitogenic signals in T cell proliferations by anti-LFA-1 (CD18, CD11a), CLA-3, and CD7 monoclonal antibodies", J. Immunol. 141(6):1919-1924 (1988)   |             |      |
|                      | C66         | CATE, et al., "Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells", Cell, 45, 685-698 (1986).   |             |      |
|                      | C67         | CERDAN, et al., "Prolonged IL-2 receptor α/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28", J. Immunol. 149(7):2255-2261 (1992)   |             |      |
|                      | C68         | CHANDRARATNA, "Tazarotene: The First Receptor-Selective Topical Retinoid for the Treatment of Psoriasis", American Academy of Dermatology, vol. 37, No. 2, pp. S12-S17, 1997.  |             |      |
|                      | C69         | CHANG et al. (1992) "T-Cell Activation Is Potentiated by Cytokines Released by Lesional Psoriatic, but Not Normal, Epidermis" Arch. Dermatol. 128:1479-1785.   |             |      |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |   |    |    |                          |                  |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |    | <b>Complete if Known</b> |                  |
|   |   |    |    | Application Number       | 10/588,323       |
|   |   |    |    | Filing Date              | February 7, 2005 |
|   |   |    |    | First Named Inventor     | MAGILAVY         |
|   |   |    |    | Group Art Unit           | 1644             |
|   |   |    |    | Examiner Name            | Unassigned       |
| Sheet   | 7 | of | 33 | Attorney Docket Number   | 253780           |


**OTHER - NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.                         | Translation |      |
|----------------------|-------------|--|-------------|------|
|                      |             |  | Yes         | No** |
|                      | C70         | CHAVIN, et al., "Prolongation of allograft and xenograft survival in mice by anti-CD2 monoclonal antibodies", Transplantation, 54(2):286-291 (1992)  |             |      |
|                      | C71         | CHIN, Y.H. et al. "Lymphocyte Recognition of Psoriatic Endothelium: Evidence for a Tissue-Specific Receptor/Ligand Interaction", J. Invest. Dermatol. 93(2) Supplemental: 82S-87S (1989).  |             |      |
|                      | C72         | CHISHOLM et al. (1994) "The effects of an immunodulatory LFA3-IgG.sub.I fusion protein on nonhuman primates," Therapeutic Immunology 1: 205-216.   |             |      |
|                      | C73         | CHRISTIANSEN, et al., "Etretinate (Tigason.RTM.) and Betamethasone Valerate (Celeston Valerate.RTM.) in the Treatment of Psoriasis", Dermatologica, vol. 165, pp. 204-207, 1982.   |             |      |
|                      | C74         | CHRISTOPHERS, et al., "The Inflammatory Infiltrate in Psoriasis", Clinics in Dermatology, vol. 13, pp. 131-135, 1995.  |             |      |
|                      | C75         | CHRISTOPHERS, et al., "Cyclosporine in Psoriasis: A Multicenter Dose-Finding Study in Severe Plaque Psoriasis", Therapy, Journal of the American Academy of Dermatology, vol. 26, No. 1, pp. 876-890, 1992.  |             |      |
|                      | C76         | CHURCH, et al., "Genomic Sequencing", Proc. Natl. Acad. Sci. U.S.A., 81, 1991-1995 (1984).   |             |      |
|                      | C77         | CLAYTON et al. (1987) "Murine and Human T11 (CD2) cDNA Sequences Suggest A Common Signal Transduction Mechanism" Eur. J. Immunol. 17: 1367-1370.   |             |      |
|                      | C78         | COHEN, et al., "Immunomodulatory Agents and Other Medical Therapies in Inflammatory Bowel Disease" Current Opinion in Gastroenterology, vol. 11, pp. 321-330, 1995.  |             |      |
|                      | C79         | COLTEN, "Pulmonary Inflammation-A Balancing Act", N Engl J Med. 1997 Apr. 10;336(15):1094-6.   |             |      |
|                      | C80         | COLVIN, et al., "Cellular and Molecular Mechanisms of Allograft Rejection", Ann Rev Med 41:361-375 (1990)  |             |      |
|                      | C81         | CONTI et al., (1990) "Effect of Monoclonal Antibodies on Primate Allograft Rejection" Crit. Rev. Immunol. 10(2): 113-130.  |             |      |
|                      | C82         | CONZELMANN et al. (1986) "Anchoring of membrane proteins via phosphatidylinositol is deficient in two classes of Thy-1 negative mutant lymphoma cells", The EMBO J., vol. 5, No. 12, pp. 3291-3296.  |             |      |
|                      | C83         | COOPER (1990) "Immunoregulation in the Skin" Current Problems in Dermatology 19:69-80.   |             |      |
|                      | C84         | COOPER (1992) "Skin-infiltrating Lymphocytes in Normal and Disordered Skin: Activation Signals and Functional Roles in Psoriasis and Mycosis Fungoides-types Cutaneous T Cell Lymphoma" J. Dermatol. 19:731-737.   |             |      |
|                      | C85         | COOPER et al. (1985) "Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of langerhans cell-dependent function is followed by appearance of T6-Dr+ cells that enhance epidermal alloantigen presentation" J. Immunol. 134(1):129-137. |             |      |
|                      | C86         | COSIMI et al.; "In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts sup.1 " (The Journal of Immunology--June 15, 1990 pp. 4604-4612).   |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |   |    |    |                          |                  |
|---|---|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   |    |    | <b>Complete if Known</b> |                  |
|   |   |    |    | Application Number       | 10/588,323       |
|   |   |    |    | Filing Date              | February 7, 2005 |
|   |   |    |    | First Named Inventor     | MAGILAVY         |
|   |   |    |    | Group Art Unit           | 1644             |
|   |   |    |    | Examiner Name            | Unassigned       |
| Sheet   | 8 | of | 33 | Attorney Docket Number   | 253780           |


| OTHER - NON PATENT LITERATURE DOCUMENTS |          |   |             |      |  |
|---|----------|---|-------------|------|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.                      | Translation |      |  |
|   |          |   | Yes         | No** |  |
|   | C87      | COSOMI et al., "Prolonged survival of nonhuman primate renal allograft recipients treated only with anti-CD4 monoclonal antibody" Surgery, 108 (2): 1990 pp. 406-414).  |             |      |  |
|   | C88      | Cosimi, et al. "Immunosuppression of Cynomolgus Recipients of Renal Allografts..." Leukocyte Adhesion Molecules (Springer-Verlog 1988) pp. 275-281  |             |      |  |
|   | C89      | COSIMI, et al., "Anti-T-Cell Monoclonal Antibodies in Transplantation Therapy", Transplantation Proc. 15(3):1889-1892 (1983)  |             |      |  |
|   | C90      | CRISPE, and Mehal, "Strange Brew: T Cells in the Liver" Immunology Today, vol. 17, No. 11, pp. 522-525, 1996.   |             |      |  |
|   | C91      | CRONSTEIN, "The Mechanism of Action of Methotrexate", Rheumatic Disease Clinics of North America, vol. 23, No. 4, pp. 739-755, 1997.  |             |      |  |
|   | C92      | CUELAR, et al., "Psoriatic Arthritis Current Developments" J. Florida M.A. 82(5):338-342 (1995)   |             |      |  |
|   | C93      | CUNNINGHAM and HARRIS (1992) "Antibody engineering--how to be human" TIBTECH 10.  |             |      |  |
|   | C94      | CUNNINGHAM et al., "Neural Cell Adhesion Molecule: Structure, Immunoglobulin-Like Domains, Cell Surface Modulation, and Alternative RNA Splicing," Science, 236, pp. 799-806 (1987).  |             |      |  |
|   | C95      | CURTIS, et al. (1992) "The Nature of Science" in Biology, 5.sup.th ed. (Worth Publishers, Inc.): 14-15  |             |      |  |
|   | C96      | DAILEY, et al., "Sequences in the Polyomavirus DNA Regulatory Region Involved in Viral DNA Replication and Early Gene Expression," J. Virology, 54 (3), pp. 739-749 (Jun. 1985).  |             |      |  |
|   | C97      | DAMLE, et al., "Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule 1 or vascular cell adhesion molecule 1 induces functional expression of CTLA-4, a second receptor for B7" J. Immunol (1994)  |             |      |  |
|   | C98      | DAMLE, et al., "Stimulation of cloned human T lymphocytes via the CD3 or CD28 molecules induces enhancement in vascular endothelial permeability to macromolecules with participation of type -1 and type-2 intercellular adhesion pathways" Eur. J. Immunol. 20 (9):1995-2003 (1990) |             |      |  |
|   | C99      | DAMLE, N., et al., "Differential Costimulatory Effects of Adhesion Molecules B7, ICAM-1, LFA-3, and VCAM-1 on Resting and Antigen-Primed CD4.sup.+ T Lymphocytes" The Journal of Immunology, vol. 148, 1985-1992, No. 7 (Apr. 1, 1992);.  |             |      |  |
|   | C100     | DANIELIAN, et al., "The Tyrosine Kinase Activity of p56.sup.kk is Increased in Human T Cells Activated via CD2", European Journal of Immunology, vol. 21, pp. 1967-1970, 1991.  |             |      |  |
|   | C101     | DAVIES, and Morris, "Physiological Parameters in Laboratory Animals and Humans" Pharmaceutical Research, vol. 10, No. 7, pp. 1093-1095, 1993.   |             |      |  |
|   | C102     | DAWE, et al., "Narrow-Band (TL-01) Ultraviolet B Phototherapy for Chronic Plaque Psoriasis: Three Times of Five Times Weekly Treatment?" British Journal of Dermatology, vol. 1, No. 38, pp. 833-839, 1998.   |             |      |  |
|   | C103     | DECKERT, et al., "CD59 molecule: A second ligand for CD2 in T cell adhesion", Eur. J. Immunol. 22:2943-2947 (1992)  |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



Please type a plus sign (+) inside this box → 

|   |            |    |    |                          |                  |
|---|------------|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |            |    |    | <b>Complete if Known</b> |                  |
|   |            |    |    | Application Number       | 10/588,323       |
|   |            |    |    | Filing Date              | February 7, 2005 |
|   |            |    |    | First Named Inventor     | MAGILAVY         |
|   |            |    |    | Group Art Unit           | 1644             |
| Examiner Name   | Unassigned |    |    |                          |                  |
| Sheet   | 9          | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |  |             |      |  |
|---|----------|--|-------------|------|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |          |  | Yes         | No** |  |
|   | C104     | DENNING et al. (1987) "Monoclonal Antibodies to CD2 and Lymphocyte Function-Associated Antigen 3 Inhibit Human Thymic Epithelial Cell-Dependent Mature Thymocyte Activation" J. Immunol. 139(8):2573-2578.   |             |      |  |
|   | C105     | DENNING et al. (1988) "Purified Lymphocyte Function-Associated Antigen-3 (LFA-3) Activates Human Thymocytes Via The CD2 Pathway" J. Immunol. 141(9): 2980-2985.  |             |      |  |
|   | C106     | DENTE, L., et al., "pEMBL: a New Family of Single Stranded Plasmids," Nucleic Acids Research, 11(6), pp. 1645-1655 (1983).   |             |      |  |
|   | C107     | Department of Health & Human Services, "International Conference on Harmonisation" Federal Register, vol. 62, No. 222, pp. 61515-61519, 1997.  |             |      |  |
|   | C108     | DING et al. (1996) "A novel murine model for the assessment of human CD2-related reagents In Vivo," J. Immunol. 157(5): 1863-1869.   |             |      |  |
|   | C109     | DINOWITZ, et al., "Recent Studies on Retrovirus-Like Particles in Chinese Hamster Ovary Cells", Developments in Biological Standardizations, vol. 76, pp. 201-207, 1991.   |             |      |  |
|   | C110     | DRAKE, et al., "Guidelines of Care for Psoriasis", Journal of American Academy of Dermatology, vol. 28, No. 4, pp. 632-637, 1993   |             |      |  |
|   | C111     | DRISCOLL, et al., "Structure of Domain 1 of Rat T Lymphocyte CD2 Antigen", Nature, vol. 353, pp. 762-765, 1991.  |             |      |  |
|   | C112     | DUSTIN et al. (1987) "Purified Lymphocyte Function-Associated Antigen 3 Binds to CD2 And Mediates T Lymphocyte Adhesion" J. Exp. Med. 165(3): 677-692.   |             |      |  |
|   | C113     | DUSTIN et al. (1987) "T Cell Activation By LFA-3 and CD2 Antibodies" FASEB J. 45:A1239 (Abstract No. 5484).  |             |      |  |
|   | C114     | DUSTIN, and Springer, "Role of Lymphocyte Adhesion Receptors in Transient Interaction and Cell Locomotion" Annual Review of Immunology, vol. 9, pp. 27-66, 1991.   |             |      |  |
|   | C115     | DUSTIN, and Springer, "T-Cell Receptor Cross-Linking Transiently Stimulates Adhesiveness Through LFA-1" Nature, vol. 341, pp. 619-624, 1989.   |             |      |  |
|   | C116     | DUSTIN, et al., "Anchoring Mechanisms for LFA-3 Cell Adhesion Glycoprotein at Membrane Surface", Nature, vol. 329, 846-848, 1987.  |             |      |  |
|   | C117     | DUSTIN, et al., "Low Affinity Interaction of Human or Rat T Cell Adhesion Molecule CD2 with Its Ligand Aligns Adhering Membranes to Achieve High Physiological Affinity", The Journal of Biological Chemistry vol. 272, No. 49, pp. 30889-30898, 1997.           |             |      |  |
|   | C118     | DUSTIN, M. L., et al., "Correlation of CD2 Binding and Functional Properties of Multimeric and Monomeric Lymphocyte Function-Associated Antigen 3," J. Exp. Med., 169, pp. 503-517 (Feb. 1989).  |             |      |  |
|   | C119     | DUVIC, et al., "Molecular Mechanisms of Tazarotene Action in Psoriasis", Journal of American Academy of Dermatology, vol. 37, No. 2, pp. S18-S24, 1997.  |             |      |  |
|   | C120     | ECONOMIDOU, et al., "Effects of Cyclosporin A on Immune Activation Markers in Patients with Active Psoriasis", Dermatology, vol. 199, pp. 144-148, 1999.   |             |      |  |
|   | C121     | EDELHOCH, "Spectroscopic Determination of Tryptophan and Tyrosine in Proteins" Biochemistry, vol. 6, No. 7, pp. 1948-1954, 1967.   |             |      |  |
|   | C122     | EHMANN, and Voorhees, "Effect of Oral Synthetic Retinoids on Keratinizing Disorders", Journal of American Academy of Dermatology, vol. 6, No. 4, pp. 692-696, 1982.  |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →




|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 10 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C123        | EKBORN, et al., "Crohn's Disease After In-Utero Measles Virus Exposure", The Lancet, vol. 348, pp. 515-517, 1996.  |             |      |  |
|   | C124        | ELDER, et al., "Efficacy and Pharmacokinetics of Two Formulations of Cyclosporine A in Patients with Psoriasis" Journal of Clinical Pharmacology, vol. 35, pp. 865-875, 1995.  |             |      |  |
|   | C125        | ELLIS, "Quality of Life Results from a Randomized Double Blind Multi Center Dose Response study of LFA3TIP in patients with Chronic Plaque Psoriasis" Am Acad Dermatol. 58th Ann Meeting March 10-15 2000. (Abstract)  |             |      |  |
|   | C126        | ELLIS, et al., "Cyclosporine for Plaque-Type Psoriasis: Results of a Multidose, Double-Blind Trial", The New England Journal of Medicine vol. 324, No. 5, pp. 276-284, 1991.   |             |      |  |
|   | C127        | ELLIS, et al., "Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes", The New England J. Med. 345(4):248-255 (2001)  |             |      |  |
|   | C128        | ENE, V. and N. D. Zinder, "Interference Resistant Mutants of Phage f1," Virology, 122, pp. 222-226 (1982).   |             |      |  |
|   | C129        | EWE, et al., "Azathioprine and Prednisolone for Active Crohn Disease", ACP Journal Club, 1994, Annals of Internal Medicine 120/2 Suppl. 1 (13).  |             |      |  |
|   | C130        | EZEKOWITZ, et al., "The Interferons: Basic Biology and Therapeutic Potential" in Therapeutic Immunology, edited by Austen et al., (Blackwell Science, Cambridge, MA, 1996) 249-263.  |             |      |  |
|   | C131        | FARBER, "Juvenile Psoriasis: Early Interventions Can Reduce Risks for Problems Later" Postgraduate Medicine vol. 103, No. 4, pp. 89-100, 1998.   |             |      |  |
|   | C132        | FARBER, et al. "Psoriasis: A Disease of the Total Skin" Journal of American Academy of Dermatology, vol. 12(1), pp. 150-156, 1985.   |             |      |  |
|   | C133        | FAULDS, et al., "Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders", Drugs, vol. 45, No. 6, pp. 953-1040, 1993.   |             |      |  |
|   | C134        | FEAGAN, et al., "Methotrexate for the Treatment of Crohn's Disease" The New England Journal of Medicine, vol. 332(5), pp. 292-297, 1995.   |             |      |  |
|   | C135        | Feagan, et al., "Methotrexate Improved Symptoms in Chronic Active Crohn Disease", ACP Journal Club, 1995, Jul.-Aug.; 123(1) 9.   |             |      |  |
|   | C136        | FEAGAN, et al., "Therapeutics and Inflammatory Bowel Disease: A Guide to the Interpretation of Randomized Controlled Trials" Gastroenterology, vol. 110, pp. 275-283, 1996.  |             |      |  |
|   | C137        | FELDMAN, et al., "The Economic Impact of Psoriasis Increases with Psoriasis Severity" Journal of American Academy of Dermatology, vol. 37(4), pp. 564-569, 1997.   |             |      |  |
|   | C138        | FELDMAN, et al., "The Self-Administered Psoriasis Area and Severity Index Is Valid and Reliable", Journal of Investigative Dermatology, vol. 106, pp. 183-186, 1996.   |             |      |  |
|   | C139        | FERGUSON et al. (1988) "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures", Ann. Rev. Biochem., vol. 57, pp. 285-320.  |             |      |  |
|   | C140        | FERACILLI, et al., "Effects of cyclosporine on joint damage in rheumatoid arthritis", Clin Exp. Rheum. 15 (Supp 17):S83-S89 (1997)   |             |      |  |
|   | C141        | Ffrench-Constant, "Pathogenesis of Multiple Sclerosis", The Lancet, vol. 343, pp. 272-278, 1994.   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 11 | of | 33 | Attorney Docket Number   | 253780           |


**OTHER - NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.    | Translation |      |
|-------------------|----------|---|-------------|------|
|                   |          |   | Yes         | No** |
|                   | C142     | FINDLAY "Purification of Membrane Proteins" Ch. 4 in Protein Purification Applications, A Practical Approach (Harris and Angel, eds) 1990 (cited for argument)  |             |      |
|                   | C143     | FINDLAY, and Khan, "Dermatology Life Quality Index (DLQI): A Simple Practical Measure for Routine Clinical Use", Clinical and Experimental Dermatology, vol. 19, pp. 210-216, 1993.   |             |      |
|                   | C144     | FINZI, et al., "A Clinical Survey of Psoriasis in Italy: 1.sub.st AISP Report" Journal of the European Academy of Dermatology and Venereology, vol. 10,pp. 125-129, 1998.   |             |      |
|                   | C145     | FINZI, et al., "Cyclosporin versus Etretinate: Italian Multicenter Comparative Trial in Severe Plaque-Form Psoriasis", Dermatology, vol. 187(suppl 1), pp. 8-18, 1993   |             |      |
|                   | C146     | FIRST, "Transplantation in the Nineties", Transplantation 53(1):1-11 (1992)   |             |      |
|                   | C147     | FISHEL, et al. "The cellular response to xenotransplantation", Curr. Surg. 47(5):345-347 (1990)   |             |      |
|                   | C148     | FISHER, "T cell adhesion", J. Exp. Clin. Hematol. 32:49-51 (1990)   |             |      |
|                   | C149     | FLEISCHER, Jr., et al., "Disease Severity Measures in a Population of Psoriasis Patients: The Symptoms of Psoriasis Correlate with Self-Administered Psoriasis Area Severity Index Scores", Journal of Investigative Dermatology, vol. 107, No. 1, pp. 26-29, 1996. |             |      |
|                   | C150     | FLEISCHER, Jr., et al., "Patient Measurement of Psoriasis Disease Severity with a Structured Instrument" Journal of Investigative Dermatology, vol. 102, No. 6, pp. 967-969, 1994.  |             |      |
|                   | C151     | FORTUNE, et al., "Quality of Life in Patient with Psoriasis: the Contribution of Clinical Variables and Psoriasis-Specific Stress", British Journal Of Dermatology, vol. 137, pp. 755-760, 1997.  |             |      |
|                   | C152     | FOX, "The Role of T Cells in the Immunopathogenesis of Rheumatoid Arthritis", Arthritis & Rheumatism, vol. 40, No. 4, pp. 598-609, 1997.  |             |      |
|                   | C153     | GAMACHE et al. (1996) "Pharmacokinetics of LFA3TIP, an immunoglobulin fusion protein, in male and female baboons," Pharmaceutical Research 13 (9 Sup.): s399 (Abstract).  |             |      |
|                   | C154     | GASGOIGNE et al., "Secretion of a chimeric T-cell receptor-immunoglobulin protein", 1987, P.N.A.S. USA, vol. 84;2936-2940.  |             |      |
|                   | C155     | GEIDER, K., et al., "A Plasmid Cloning System Utilizing Replication and Packaging Functions of the Filamentous Bacteriophage fd," Gene, 33, pp. 340-349 (1985).   |             |      |
|                   | C156     | Genmab Press release 48/2002 "HuMAX CD-4 in combination therapy not effective in Rheumatoid Arthritis"  |             |      |
|                   | C157     | GEORGOURAS, et al. "Systemic Treatment of Severe Psoriasis", Australasian Journal of Dermatology, vol. 38, pp. 171-182, 1997.   |             |      |
|                   | C158     | GIMENEZ-ARNAU, et al., "Psoriasis: bases de actuacion terapeutica", Act. Dermatolog.3:159-171(1998)   |             |      |
|                   | C159     | GIORGI, et al, "Immunosuppressive Effect and Immunogenicity of OKT11A monoclonal antibody in monkey allograft recipients", Transplantation Proc. 15(1):639-642 (1983)   |             |      |
|                   | C160     | GISMONDI, et al., "Triggering through CD16 or Phorbol Esters Enhances Adhesion of NK Cells to Laminin via Very Late Antigen 6", Journal of Experimental Medicine, vol. 176,pp. 1251-1257,1992.  |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 12 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.     | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C161        | GOEBEL, et al., "Drug Trials in Inflammatory Bowel Diseases 1993-1995: A Survey Conducted by the IOIBD", Inflammatory Bowel Diseases, vol. 2, pp. 265-267, 1996.   |             |      |  |
|   | C162        | GOEDKOOOP et al., "Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis", Arch. Dermatol. Res. 295:465-473 (2004)  |             |      |  |
|   | C163        | GOLDMAN, et al., "OKT3-Induced Cytokine Release Attenuation by High-Dose MethilPrednisolone", Lancet. Sep. 30, 1989;2(8666):802-3.   |             |      |  |
|   | C164        | GOLLNICK, et al., "Acitretin* versus Etretnate in Psoriasis: Clinical and Pharmacokinetic Results of a German Multicenter Study", Journal of American Academy of Dermatology, vol. 19, No. 3, pp. 458-468, 1988.   |             |      |  |
|   | C165        | GOLLOB, et al., "CD2 Regulates Responsiveness of Activated T Cells to Interleukin 12", Journal of Experimental Medicine, vol. 182, pp. 721-731, 1995.  |             |      |  |
|   | C166        | GONZALES-RAMOS et al. (1992) "APC-Targeted Immunointervention in Psoriasis: Blockade of LFA-3-CD2 and ICAM 1-LFAI Ligand Pairing Blocks Autoreactivity to Lesional Epidermis" Clinical Research 40(2):500A.  |             |      |  |
|   | C167        | GORDON, et al., "Treatment of psoriasis with alefacept", Arch. Dermatol. 139: 1563-1570 (2003)   |             |      |  |
|   | C168        | GOTTLIEB, "The Challenges of Treating Moderate to Severe Psoriasis", International Journal of Dermatology, vol. 36(suppl 1), pp. 41-44, 1997.  |             |      |  |
|   | C169        | GREAVES, and Weinstein, "Treatment of Psoriasis", The New England Journal of Medicine, vol. 332, No. 9, pp. 581-588, 1995.   |             |      |  |
|   | C170        | GREENBERG, et al., "Oral Budesonide for Active Chrohn's Disease", The New England Journal of Medicine, vol. 331, No. 13, pp. 836-845, 1994.  |             |      |  |
|   | C171        | GREGERSEN, et al., "A CD4: immunoglobulin fusion protein with antiviral effects against HIV", Arch. Virol. 111:29-43 (1990)  |             |      |  |
|   | C172        | GROSSMAN, et al., "A Novel Therapeutic Approach to Psoriasis with Combination Calcipotriol Ointment and Very-Low-Dose Cyclosporine: Results of a Multicenter Placebo-Controlled Study", Journal of American Academy of Dermatology, vol. 31, No. 1, pp. 68-74, 1994. |             |      |  |
|   | C173        | GROSSMAN et al., "Long-term Safety of Cyclosporine in the Treatment of Psoriasis", Archives of Dermatology, vol. 132, pp. 623-629, 1996.   |             |      |  |
|   | C174        | GROSVELD, et al., "The Construction of Cosmid Libraries Which Can Be Used to Transform Eukaryotic Cells", Nucl. Acids. Res., 10(21), 6715-6732 (1982).   |             |      |  |
|   | C175        | GUBLER, et al., "A Simple and Very Efficient Method for Generating cDNA Libraries", Gene, 25, 263-269 (1983).  |             |      |  |
|   | C176        | GUCKIAN, et all., "Immunomodulation at the Initiation of Phototherapy and photochemotherapy", Photodermatology, Photoimmunology & Photomedicine, vol. 11, pp. 163-169, 1995.   |             |      |  |
|   | C177        | GULLIVER, et al., Increased Bioavailability and Improved Efficacy, in Severe Psoriasis, of a New Microemulsion Formulation of Cyclosporin*, British Journal Of Dermatology, vol. 135(suppl 48), pp. 35-39, 1996.   |             |      |  |
|   | C178        | GUZZO, "Recent Advances in the Treatment of Psoriasis", Dermatologic Clinics, vol. 15, No. 1, pp. 59-68, 1997.   |             |      |  |
|   | C179        | HAFLER, et al., "Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis", J. Immunol. 141(1):131-138 (1988)   |             |      |  |
| Examiner Signature                      |             | Date Considered  |             |      |  |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 13 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C180        | HALE, et al. "Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation", J. Immunol. 149(12):3809-3816 (1992)                                    |             |      |  |
|   | C181        | HAMBLIN, "From Dendritic Cells to Tumour Vaccines", The Lancet, vol. 347, pp. 705-706, 1996.   |             |      |  |
|   | C182        | HANAUER, "Inflammatory Bowel Disease", Drug Therapy, vol. 334, No. 13, pp. 841-848, 1996.  |             |      |  |
|   | C183        | HANAUER, "Medical Therapy of Ulcerative Colitis" The Lancet, vol. 342, pp. 412-417, 1993.  |             |      |  |
|   | C184        | HARDMAN, et al., "Active Psoriasis and Profound CD4.sup.+ Lymphocytopenia", British Journal Of Dermatology, vol. 136, pp. 930-932, 1997.   |             |      |  |
|   | C185        | HARRIS and Emery (1993) "Therapeutic antibodies--the coming of age" TIBTECH 11: 42-44.   |             |      |  |
|   | C186        | HAWKE, et al., "Autoimmune T Cells in Myasthenia Gravis: Heterogeneity and Potential for Specific Immunotargeting", Immunology Today, vol. 17, No. 7, pp. 307-311, 1996.   |             |      |  |
|   | C187        | HAWKES, et al., "A Dot-Immunobinding Assay for Monoclonal and Other Antibodies", Anal. Biochem., 119, 142-147 (1982).  |             |      |  |
|   | C188        | HAYNES, B.F. et al. "Synovial microenvironment-T cell interactions", Arthritis and Rheum. 31 (8): 947-955 (1988).  |             |      |  |
|   | C189        | HE et al., "Phosphatidylinositol is Involved in the Membrane Attachment of NCAM-120, the Smallest Component of the Neural Cell Adhesion Molecule," EMBO Journal, 5, (10), pp. 2489-2494 (1986).  |             |      |  |
|   | C190        | HEBEL, et al., "Suppression of the immune response by a soluble complement receptor of B lymphocytes", Science 254(5028):102-105 (1991) (cited for argument)   |             |      |  |
|   | C191        | HEIJ (La Heij), et al., "Adhesion molecules in iris biopsy specimens from patients with uveitis", Br. J. Ophthamol. 82(4):432-437 (1998)   |             |      |  |
|   | C192        | HENSELER, "The Genetics of Psoriasis", Journal of American Academy of Dermatology, vol. 37, No. 2, pp. S1-S11, 1997.   |             |      |  |
|   | C193        | HENSELER, and Christophers, "Disease Concomitance in Psoriasis", Journal of American Academy of Dermatology, vol. 32, pp. 982-986, 1997.   |             |      |  |
|   | C194        | HENSELER, and Christophers, "Psoriasis of Early and Late Onset: Characterization of Two Types of Psoriasis Vulgaris", Journal of American Academy of Dermatology, vol. 13, No. 3, pp. 450-456, 1995.   |             |      |  |
|   | C195        | HERBIN, et al., "Automated Registration of Dissimilar Images: Application to Medical Imagery", Computer Vision, Graphics, and Image Processing, vol. 47, pp. 77-88, 1989.  |             |      |  |
|   | C196        | HEWICK, et al., "A Gas-Liquid Solid Phase Peptide and Protein Sequenator", J. Biol. Chem., 256(15), 7990-7997 (1981).  |             |      |  |
|   | C197        | HIRAMINE, et al., "Differential Effect of Cyclosporine in Vivo on the Distribution of T cell Subsets in the Thymus, Spleen, and Lymph Nodes", Transplantation, vol. 47, No. 3, pp. 499-503, 1989.  |             |      |  |
|   | C198        | HIRANO, et al., "Individual Pharmacodynamics Assessed by Antilymphocyte Action Predicts Clinical Cyclosporine Efficacy in Psoriasis", Clinical Pharmacology & Therapeutics, vol. 63, No. 4, pp. 465-470, 1998.   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 14 | of | 33 | Attorney Docket Number   | 253780           |

**OTHER - NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|----------------------|-------------|--|-------------|------|
|                      |             |  | Yes         | No** |
|                      | C199        | HO, et al., "Intermittent Short Courses of Cyclosporin (Neoral.RTM.) for Psoriasis Unresponsive to Topical Therapy: A 1-Year Multicentre, Randomized Study", British Journal Of Dermatology, vol. 141, pp. 283-291, 1999.  |             |      |
|                      | C200        | HOFFMANN, et al., "Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34", Annals of Rheumatic Diseases, 56 (12) : 716-722 (1997)  |             |      |
|                      | C201        | HOLLSBERG, et al., "Increased protein kinase C activity in human memory T cells", Cell. Immunol. 149(1):170-179 (1993)   |             |      |
|                      | C202        | HONEYMAN, et al., "Low-Dose Cyclosporine a Improves Severe Disabling Psoriasis in Latin America", International Journal of Dermatology, vol. 34, pp. 583-588, 1995.  |             |      |
|                      | C203        | HOOKS et al., "Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation", Pharmacotherapy 11(1):25-37 (1991)  |             |      |
|                      | C204        | HOPKINS, et al., "A double-Blind Controlled Trial of Etretinate (Tigason) and Ibuprofen in Psoriatic Arthritis", Annals of the Rheumatic Diseases, vol. 44, pp. 189-193, 1985.   |             |      |
|                      | C205        | HOWARD et al. (1981) A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation: J. Immunol. 126(6):2117-2122.  |             |      |
|                      | C206        | HUGHES et al. (1990) "Endothelial Cells Augment T Cell Interleukin 2 production by a Contact-Dependent Mechanism involving CD2/LFA-3 Interaction" J. Exp. Med. 171:1453-1467.  |             |      |
|                      | C207        | HUGHES et al. (1990) "The Endothelial Cell As A Regulator Of T-Cell Function" Immunol. Rev. 117, 85-102.   |             |      |
|                      | C208        | HUGOT, et al., "Mapping of a Susceptibility Locus for Crohn's Disease on Chromosome 16", Nature, vol. 379, pp. 821-823, 1996.  |             |      |
|                      | C209        | HUNT, et al., "Generalized Pustular Psoriasis Responsive to PUVA and Oral Cyclosporin Therapy", Australasian Journal of Dermatology, vol. 38, pp. 199-201, 1997.   |             |      |
|                      | C210        | HYMAN (1985) "Cell-surface-antigen mutants of haematopoietic cells", Biochem J., vol. 225, pp. 27-40.  |             |      |
|                      | C211        | IEIRI et al., "Evaluation of the Therapeutic Range of Whole Blood Cyclosporin Concentration in the Treatment of Psoriasis", International Journal of Clinical Pharmacology and Therapeutics, vol. 34, No. 3, pp. 106-111, 1996.                                  |             |      |
|                      | C212        | IKEMIZU, et al., "Crystal Structure of the CD2-Binding Domain of CD58 (Lymphocyte Function-Associated Antigen 3) at 1.8-ANG. Resolution", Proceedings of the National Academy of Science, vol. 96, pp. 4289-4294, 1999.  |             |      |
|                      | C213        | INOUE, et al., "Anti-adhesion molecule therapy in Theiler's murine encephalomyelitis virus-induced demyelinating disease", Int. Immunol. 9(12):1837-1847 (1997)  |             |      |
|                      | C214        | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US88/01924, dated October 7, 1988   |             |      |
|                      | C215        | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US89/03652, dated February 7, 1990  |             |      |
|                      | C216        | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US92/02050, dated August 12, 1992   |             |      |
|                      | C217        | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US92/08754, dated June 28, 1993   |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →




|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 15 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |  |             |      |
|---|----------|--|-------------|------|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|   |          |  | Yes         | No** |
|   | C218     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US92/08755, dated July 8, 1993  |             |      |
|   | C219     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US99/20026, dated May 8, 2000   |             |      |
|   | C220     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US02/02314, dated June 11, 2002   |             |      |
|   | C221     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US02/21631, dated June 25, 2003   |             |      |
|   | C222     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/16265, dated October 26, 2005  |             |      |
|   | C223     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/15531, dated February 24, 2006   |             |      |
|   | C224     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/03907, dated October 3, 2005   |             |      |
|   | C225     | INTERNATIONAL SEARCHING AUTHORITY, International Search Report for International Application No. PCT/US05/39070, dated April 27, 2007  |             |      |
|   | C226     | IP, et al., Structural Characterization of the N-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G, Archives of Biochemistry and Biophysics, vol. 308, No. 2, pp. 387-399, 1994.  |             |      |
|   | C227     | ISAACS, et al., "Humanized Anti-CD4 Monoclonal Antibody Therapy of Autoimmune and Inflammatory Disease", Clinical and Experimental Immunology, vol. 110, pp. 158-166, 1997.  |             |      |
|   | C228     | JEFFERIS, and Lund, "Glycosylation of Antibody Molecules: Structural and Functional Significance", Chemical Immunology, vol. 65, pp 111-113, 1997  |             |      |
|   | C229     | JEMEC, and Wulf, "The Applicability of Clinical Scoring Systems: SCORAD and PASI in Psoriasis and Atopic Dermatitis", Acta Derm Venereol (Stockholm), vol. 77, pp. 392-393, 1997.  |             |      |
|   | C230     | JENKINS, et al., "CD28 Delivers A Constitutatory Signal Involved in Antigen-Specific IL-2 Production by Human T Cells", The Journal of Immunology, vol. 147(8), pp. 2461-2466, 1991.   |             |      |
|   | C231     | JOHNSON, "On Teaching Dermatology to Nondermatologists", Arch Dermatol, vol. 130, pp. 850-852, 1994.   |             |      |
|   | C232     | JONES, et al., "Crystal Structure at 2.8.Å Resolution of a Soluble Form of the Cell Adhesion Molecule CD2" Nature, vol. 360, pp. 232-239, 1992.  |             |      |
|   | C233     | JONKER, "Immunosuppressive Therapy by monoclonal anti-T lymphocyte subset antibodies", Leukocyte Typing III (Oxford Univ. Press 1987) pp.923-927.  |             |      |
|   | C234     | JONKER, et al., "The Influence of OKT8F Treatment on Allograft Survival in Rhesus Monkeys", Transplantation 41(4): 431-435 (1986)  |             |      |
|   | C235     | JONKER, et al., "Effects of in vivo administration of monoclonal antibodies specific for human T cell subpopulations on the immune system in a rhesus monkey model", Transplantation 35(6): 521-526 (1983)   |             |      |
|   | C236     | JUNE, "Increases in Tyrosine Phosphorylation are Detectable Before Phospholipase C Activation After T Cell Receptor Stimulation", The Journal of Immunology, vol. 144, No. 5, pp. 1591-1599, 1990.   |             |      |
| Examiner Signature                      |          | Date Considered  |             |      |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 16 | of | 33 | Attorney Docket Number   | 253780           |


| OTHER - NON PATENT LITERATURE DOCUMENTS |             |   |             |      |  |
|---|-------------|---|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.                  | Translation |      |  |
|   |             |   | Yes         | No** |  |
|   | C237        | KANG, et al., "Calcipotriene-Induced Improvement in Psoriasis is Associated with Reduced Interleukin-8 and Increased Interleukin-10 levels within Lesions", British Journal of Dermatology, vol. 138, pp. 77-83, 1998.  |             |      |  |
|   | C238        | KANNER, et al., "CD2/LFA-3 Ligation Induces Phospholipase-C.gamma.1 Tyrosine Phosphorylation and Regulates CD3 Signaling", The Journal of Immunology, vol. 148, No. 7, pp. 2023-2029, 1992.   |             |      |  |
|   | C239        | KANTOR, et al., "Double-Blind Bilateral Paired Comparison of 0.05% Halobetasol Propionate Cream and its Vehicle in Patients with Chronic Atopic Dermatitis and Other Eczematous Dermatoses", Journal of the American Academy of Dermatology, vol. 25, No. 6, pp. 1184-1186. 1991. |             |      |  |
|   | C240        | KAPLAN et al. (1987) "Distribution and Turnover of Langerhans Cells During Delayed Immune Responses in Human Skin" J. Exp. Med. 165:763-776.  |             |      |  |
|   | C241        | KAPLON et al. (1996) "Short course single agent therapy with an LFA-3-IgG.sub.I fusion protein prolongs primate cardiac allograft survival." Tranplantation 61(3): 356-363.   |             |      |  |
|   | C242        | KASAHARA, et al., "Role of interleukin 6 for differential responsiveness of naive and memory CD4+ T cells in CD2-mediated activation", J. Exp. Med. 172 (5):1419-1424 (1990)  |             |      |  |
|   | C243        | KATO, et al., "CD48 is a Counter-Receptor for Mouse CD2 and is Involved in T Cell Activation", Journal of Experimental Medicine, vol. 176, pp. 1241-1249, 1992.   |             |      |  |
|   | C244        | KAUFMAN, and Sharp, "Amplification and Expression of Sequences of Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene", Journal of Molecular Biology, vol. 159, pp. 601-621, 1982.  |             |      |  |
|   | C245        | KAUFMAN, and Sharp, "Construction of a Modular Dihydrofolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression", Molecular and Cellular Biology, vol. 2, No. 11, pp. 1304-1319, 1982.  |             |      |  |
|   | C246        | KAWAI, et al., "Intrathecal administration of antibodies against LFA-1 and against ICAM-1 suppresses experimental allergic encephalomyelitis in rats", Cell Immunol. 171(2):262-268 (1996)  |             |      |  |
|   | C247        | KELSO, Th1 and Th2 Subsets: Paradigms Lost?, Immunology Today, vol. 16, No. 8, pp. 374-379, 1995.   |             |      |  |
|   | C248        | KENT, S. B. H., "Chemical Synthesis of Peptides and Proteins," Ann. Rev. Biochem., 57, pp. 957-989 (1988).  |             |      |  |
|   | C249        | KILEEN et al., "The MRC OX-45 Antigen of Rat Leukocytes and Endothelium is in a Subset of the Immunoglobulin Superfamily with CD2, LFA-3 and Carcinoembryonic Antigens", The EMBO Journal, vol. 7, No. 10, pp. 3087-3091, 1988.   |             |      |  |
|   | C250        | KIMBALL, Introduction to Immunology, 1983, (Ed.), Macmillan Publishing Co., New York, NY, 1983.   |             |      |  |
|   | C251        | KINGSTON, et al., "Etrelin Therapy for Severe Psoriasis", Arch Dermatol, vol. 123, pp. 55-58, 1987.   |             |      |  |
|   | C252        | KIRKHAM, et al., "Chimeric CD7 monoclonal antibody therapy in Rheumatoid arthritis", J. Rheumatol. 19(9) 1348-1352 (1992).  |             |      |  |
|   | C253        | KNOX, et al., "Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides", Blood 77(1):20-30 (1991).   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



Please type a plus sign (+) inside this box → 


|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 17 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C254        | KOHLER, G. and C. Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," Nature, 256, pp. 495-497 (Aug. 7, 1975).  |             |      |  |
|   | C255        | KOLLIAS, "Letter to the Editor: Simple Changes to PUVA Phototherapy May Minimize to the Photocarcinogenic Risks", Photodermatology, Photoimmunology, & Photomedicine, vol. 15, pp. 205, 1999.  |             |      |  |
|   | C256        | KOO, "Neoral in Psoriasis Therapy: Toward a New Perspective", International Journal of Dermatology, vol. 36, pp. 25-29, 1997.  |             |      |  |
|   | C257        | KOO, "Population-Based Epidemiological Study of Psoriasis with Emphasis on Quality of Life Assessment", Psychodermatology, vol. 14, No. 3, pp. 485-496, 1996.  |             |      |  |
|   | C258        | KOO, "Systematic Sequential Therapy of Psoriasis: A New Paradigm for Improved Therapeutic Results", Journal of the American Academy of Dermatology, vol. 41, No. 3, pp. S25-S28, 1999.   |             |      |  |
|   | C259        | KOO, et al., "Mometasone Furoate 0.1%-Salicylic Acid 5% Ointment Versus Mometasone Furoate 0.1% Ointment in the Treatment of Moderate-to-Severe Psoriasis: A Multicenter Study", Clinical Therapeutics, vol. 20, No. 2, pp. 283-291, 1998.                       |             |      |  |
|   | C260        | KOSHY, et al., "Increased Expression of CD40 Ligand on Systemic Lupus Erythematosus Lymphocytes", Journal of Clinical Investigation, vol. 98, No. 3, pp. 826-837, 1996.  |             |      |  |
|   | C261        | KOYASU et al. (1990), "Role of Interaction Of CD2 Molecules With Lymphocyte Function-Associated Antigen 3 In T-Cell Recognition of Nominal Antigen" Proc. Natl. Acad. Sci. USA 87: 2603-2607.  |             |      |  |
|   | C262        | KRAAN et al., "Alefacept Treatment in Psoriatic Arthritis" Arthritis Rheum. 46(10):2776-2784 (2002)  |             |      |  |
|   | C263        | KRAGBALLE, et al., "A Double-Blind Comparison of Acitretin and Etretinate in the Treatment of Severe Psoriasis", Acta Derm Venereol (Stockh), vol. 69, pp. 35-40, 1989.  |             |      |  |
|   | C264        | KRANZ et al., "Immunoprecipitation of Cell Surface Structures of Cloned Cytotoxic T Lymphocytes by Clone-Specific Antisera," Proc. Natl. Acad. Sci. U.S.A., vol. 81, pp. 573-77 (1984).  |             |      |  |
|   | C265        | KRENSKY (1990) "The Human Cytolytic T Lymphocyte Response to Transplantation Antigens" Pediatric Res. 19(12):1231-1234.  |             |      |  |
|   | C266        | KRENSKY et al. (1983) "The Functional Significance, Distribution, And Structure Of LFA-1, LFA-2, And LFA-3: Cell Surface Antigens Associated With CTL-Target Interactions" J. Immunol. 131(2):611-616.   |             |      |  |
|   | C267        | KRENSKY et al. (1984) "Human Lymphocyte Function Associated Antigens" Surv. Immunol. Res. 3:39-44.   |             |      |  |
|   | C268        | KRUEGER, et al., "Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking", J. Inves. Derm. 115:333 (2000) (Abstract)                             |             |      |  |
|   | C269        | KRUEGER "Efficacy and Safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis." Am Acad Dermatol. 58th Ann Meeting March 10-15 2000. (Abstract)  |             |      |  |
|   | C270        | KRUEGER, and Duvic, "Epidemiology of Psoriasis: Clinical Issues", The Journal of Investigative Dermatology, vol. 102, No. 6, pp. 14S-18S, 1994.  |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 18 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |  |             |      |  |
|---|----------|--|-------------|------|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |          |  | Yes         | No** |  |
|   | C271     | KRUEGER, Efficacy and Safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis. From Gene to Clinic Congress. AMEVIVE™ Breakfast Meeting Dec. 3, 1999 p.1.  |             |      |  |
|   | C272     | KRUEGER, et al., "The Safety and Efficacy of Tazarotene Gel, a Topical Acetylenic Retinoid, in the Treatment of Psoriasis", Arch Dermatol, vol. 134, pp. 57-60, 1998.  |             |      |  |
|   | C273     | KULLAVANIJAYA, and Kulthanan, "Clinical Efficacy and Side Effects of Acitrtin on the Disorders of Keratinization: A One-Year Study", The Journal of Dermatology, vol. 20, pp. 501-506, 1993.   |             |      |  |
|   | C274     | KUMAR, et al., "Methotrexate in Childhood Psoriasis", Pediatric Dermatology, vol. 11, No. 3, 271-273, 1994.  |             |      |  |
|   | C275     | KUMAR, et al., "Short Term Methotrexate Therapy in Psoriasis", Indian J Med Res, vol. 100, pp. 277-280, 1994.  |             |      |  |
|   | C276     | KUPPER, "Immune and inflammatory processes in cutaneous tissues: mechanisms and speculations", J.Clin. Invest. 86:1783-1789 (1990)   |             |      |  |
|   | C277     | LABURTE, et al., "Efficacy and Safety of Oral Cyclosporin A (CyA; Sandimmun.RTM.) for Long-Term Treatment of Chronic Severe Plaque Psoriasis", British Journal of Dermatology, vol. 130, pp. 366-375, 1994.  |             |      |  |
|   | C278     | LAI et al., "Two Forms of TB236/Myelin-Associated Glyco Protein, a Cell Adhesion Molecule for Postnatal Neural Development, are Produced by Alternative Splicing," Proc. Natl. Acad. Sci. U.S.A., 84, pp. 4337-4441 (1987).                                      |             |      |  |
|   | C279     | LAI et al., "Solid-State Chemical Stability of Proteins and Peptides", Journal of Pharmaceutical Sciences, vol. 88, No. 5, pp. 489-500, 1999.  |             |      |  |
|   | C280     | LAMBERT, et al., "Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their Newborns", The Journal of Infectious Diseases, vol. 175, pp. 283-291, 1997.            |             |      |  |
|   | C281     | LAMBERT, J. M. et al., "Purified Immunotoxins That Are Reactive With Human Lymphoid Cells," J. Biol. Chem., 260(22), pp. 12035-12041 (1985).   |             |      |  |
|   | C282     | LANGFORD, et al., "Use of Cytotoxic Agents and Cyclosporine in the Treatment of Autoimmune Disease", Annals of Internal Medicine, vol. 129, No. 1, pp. 49-58, 1998.  |             |      |  |
|   | C283     | LANIGAN, "Treatment of Psoriasis with the Pulsed Dye Laser", Journal of the American Academy of Dermatology, vol. 37, No. 2, pp. 288-289, 1997.  |             |      |  |
|   | C284     | LARSON and Springer (1990) "Structure and function of leukocyte integrins" Immunol. Revs. 114:181-217.   |             |      |  |
|   | C285     | LAUHARANTA, and Geiger, "A Double-Blind Comparison of Acitretin and Eretinate in Combination with Bath PUVA in the Treatment of Extensive Psoriasis", British Journal of Dermatology, vol. 121, 107-112, 1989  |             |      |  |
|   | C286     | LAUHARANTA, et al., "A Clinical Evaluation of the Effects of an Aromatic Retinoid (Tigason), Combination of Retinoid and PUVA, and PUVA Alone in Severe Psoriasis", British Journal of Dermatology, vol. 104, pp. 325-332, 1981.                                 |             |      |  |
|   | C287     | LE et al. (1987) "Anti-LFA-3 Monoclonal Antibody Induced Interleukin 1 (IL 3) Release by Thymic Epithelial (TE) Cells and Monocytes" FASEB J. 46(3):447 Abstract 761.  |             |      |  |
|   | C288     | LE et al. (1990) "Ligan Binding to the LFA-3 Cell Adhesion Molecule Induces IL-1 Production By Human Thymic Epithelial Cells" J. Immunol. 144:4541-4547.   |             |      |  |
| Examiner Signature                      |          | Date Considered  |             |      |  |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 19 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |   |             |      |  |
|---|----------|---|-------------|------|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.          | Translation |      |  |
|   |          |   | Yes         | No** |  |
|   | C289     | LEBWOHL, et al., "Interactions Between Calcipotriene and Ultraviolet Light", Journal of the American Academy of Dermatology, vol. 37, No. 1, pp. 93-95, 1997.   |             |      |  |
|   | C290     | LEBWOHL, et al., "Once-Daily Tazarotene Gel Versus Twice-Daily Flucanide Cream in the Treatment of Plaque Psoriasis", Journal of the American Academy of Dermatology, vol. 38, No. 5, pp. 705-711, 1998.  |             |      |  |
|   | C291     | LEDO, et al., "Acitretin (Ro 10-1670) in the Treatment of Severe Psoriasis: A Randomized Double-Blind Parallel Study Comparing Acitretin and Eretinate", International Journal of Psoriasis, vol. 27, No. 9, pp. 656-659, 1988.   |             |      |  |
|   | C292     | LEMSTER, et al., "FK 506 Inhibits Cytokine Gene and Adhesion Molecule Expression in Psoriatic Skin Lesions", Annals of New York Academy of Sciences, vol. 696, pp. 250-256, 1993.   |             |      |  |
|   | C293     | LENNARD-JONES, "Defining Ulcer Depth in Colitis", The Lancet, vol. 347, pp. 1708, 1996.   |             |      |  |
|   | C294     | LETVIN, et al., "T Lymphocyte Surface Antigens in Primates", European Journal of Immunology, vol. 13, pp. 345-347, 1983.  |             |      |  |
|   | C295     | LEY, et al., "The T Cell Receptor/CD3 Complex and CD2 Stimulate the Tyrosine Phosphorylation of Indistinguishable Patterns of Polypeptides in the Human T Leukemic Cell Line Jurkat", European Journal of Immunology, vol. 21, pp. 2203-2209, 1991.                       |             |      |  |
|   | C296     | LI, et al., "Enhancement of B cell responses by the interaction of CD2 with LFA-3", J. Tongji Med. Univ. 12(2):71-74 (1992)   |             |      |  |
|   | C297     | LIAO, T., et al., "Modification of Sialyl Residues of Sialoglycoprotein(s) of the Human Erythrocyte Surface," J. Biol. Chem., 248(23), pp. 8247-8253 (Dec. 10, 1973).   |             |      |  |
|   | C298     | LICHTIGER, et al., "Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy", The New England Journal of Medicine, vol. 330, No. 26, pp. 1841-1845, 1994.   |             |      |  |
|   | C299     | LINDELOF, "Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis", Drug Safety, vol. 20, No. 4, pp. 289-297, 1999.   |             |      |  |
|   | C300     | LLEWELLYN-SMITH, et al., "Effects of Anti-CD4 Antibody Treatment on Lymphocyte Subsets and Stimulated Tumor Necrosis Factor Alpha Production: A Study of 29 Multiple Sclerosis Patients Entered into a Clinical Trial of cM-T412", Neurology, vol. 48, pp. 810-816, 1997. |             |      |  |
|   | C301     | LORINCZ, "Cutaneous T-Cell Lymphoma (Mycosis Fungoides)", The Lancet, vol. 347, pp. 871-876, 1996.  |             |      |  |
|   | C302     | LOTTI, et al., "Neuropeptides and Skin Disorders. The New Frontiers of Neuro-Endocrine-Cutaneous Immunology", International Journal of Dermatology, vol. 38(9), pp. 673-675, 1999.  |             |      |  |
|   | C303     | LOW, "Biochemistry of the Glycosyl-Phosphatidylinositol Membrane Protein Anchors," Biochem. J., 244, pp. 1-13 (1987).   |             |      |  |
|   | C304     | LOWE, "Initiating Neoral.RTM. Therapy", International Journal of Dermatology, vol. 36(suppl. 1), pp. 30-33, 1997.   |             |      |  |
|   | C305     | LUDDEN, "Population Pharmacokinetics", Journal of Clinical Pharmacology, vol. 28, pp. 1059-1063, 1998.  |             |      |  |
|   | C306     | MACKAY, et al., "Naive and Memory T Cells Show Distinct Pathways of Lymphocyte Recirculation", J Exp Med. 1990 Mar. 1;171(3):801-17.  |             |      |  |
| Examiner Signature                      |          | Date Considered   |             |      |  |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 20 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C307        | MAGILAVY, et al., "Targeting CD2 for immunotherapy: results of a phase 1 trial with a LFA-3/IgG Fe fusion protein", Arthritis Rheum.40(9-suppl.): S176 (1997) (Abstract)   |             |      |  |
|   | C308        | MAGILAVY, et al., "Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP) : Selective modulation of CD45RO+lymphocytes", J. Invest. Dermatol 112(4):609 (1999) (Abstract)  |             |      |  |
|   | C309        | MAHRLE, et al., "Anti-Inflammatory Efficacy of Low-Dose Cyclosporin A in Psoriatic Arthritis. A Prospective Multicentre Study", British Journal of Dermatology, vol. 135, pp. 752-757, 1996.   |             |      |  |
|   | C310        | MAJEAU et al. (1994), "Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses," J. of Immunol. 152 (6): 2753-2767 (1994).  |             |      |  |
|   | C311        | MAJEAU, et al., "Low Affinity Binding of an LFA-3/IgG1 Fusion Protein to CD2+ T Cells is Independent of Cell Activation", Cell Adhesion and Communication, vol. 7, No. 3, pp. 267-279, 1999.   |             |      |  |
|   | C312        | MAJEWSKI, et al., "Papillomavirus and Autoimmunity in Psoriasis", Immunology Today, vol. 20, No. 10, pp. 475-476, 1999.  |             |      |  |
|   | C313        | MAKGOBA et al. (1989) "The CDA2-LFA-3 And LFA-1-ICAM Pathways: Relevance to T-Cell Recognition" Immunol. Today 10(12):417-422.   |             |      |  |
|   | C314        | MAKGOBA et al., "Human T Cell Rosetting is Mediated by LFA-3 on Autologous Erythrocytes," Journ. Immunol., vol. 138(11), pp. 3587-89 (1987).   |             |      |  |
|   | C315        | MANIATIS, et al., "Extraction, Purification, and Analysis of mRNA from Eukaryotic Cells", Molecular Cloning, A Laboratory Manual187-209 (Cold Spring Harbor Laboratory, 1982).   |             |      |  |
|   | C316        | MARCH, et al., "A Simplified Method for Cyanogen Bromide Activation of Agarose for Affinity Chromatography", Anal. Biochem., 60, 149-152 (1974).   |             |      |  |
|   | C317        | MARTZ and Gromkowski (1985) "Lymphocyte Function-Associated Antigens: Regulation of Lymphocyte Adhesions In Vitro And immunity In Vivo" Mechanisms of Cell-Mediated Cytotoxicity II (Plenum Press, 1985) pp291-310.  |             |      |  |
|   | C318        | MATIS (1990) "The molecular basis of T-cell specificity" Ann. Rev. Immunol. 8:65-82.   |             |      |  |
|   | C319        | MATSUYAMA, et al., "The Quantitative and Qualitative Defect of CD4+ CD45RO+ Memory-Type T Cells are Involved in the Abnormality of TH1 Immunity in Atopic Dermatitis Patients", Clinical and Experimental Allergy, vol. 29, pp. 687-694, 1999.                   |             |      |  |
|   | C320        | MAXAM et al., "Sequencing End-Labeled DNA with Base-Specific Chemical Cleavages", Methods in Enzymology, 65:499-560 (Academic Press,1980).   |             |      |  |
|   | C321        | MAXAM, et al., "A New Method for Sequencing DNA", Proc. Natl. Acad. Sci., 74, 560-564 (1977).  |             |      |  |
|   | C322        | MAZZANTI, et al., "Methotrexate and Cyclosporin Combined Therapy in Severe Psoriatic Arthritis. A Pilot Study", Acta Derm Venereol (Stockh), Suppl. 186, pp. 116-117, 1994.  |             |      |  |
|   | C323        | McFARLAND, "Complexities in the Treatment of Autoimmune Disease", Science, vol. 274, pp. 2037-2038, 1996.  |             |      |  |
|   | C324        | MEFFERT, and Sonnichsen, "Acitrecin in the Treatment of Severe Psoriasis: A Randomized Double-Blind Study Comparing Acitrecin and Etretinate", Acta Derm Venereol (Stockh), Suppl.146, pp. 176-177, 1989.  |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 21 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C325        | MEFFERT, et al., "Low-Dose (1.25 mg/kg) Cyclosporin A: Treatment of Psoriasis and Investigation of the Influence on Lipid Profile", Acta Derm Venereol (Stockh), vol. 77, pp. 137-141, 1997.   |             |      |  |
|   | C326        | MEIER et al (1995) "Immunomodulation by LFA3TIP, an LFA-3/IgG.sub.I fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers," Therapeutic Immunology 2(2): 159-171.  |             |      |  |
|   | C327        | MEINGASSNER, et al., "A Novel Anti-Inflammatory Drug, SDZ ASM 981, for the Topical and Oral Treatment of Skin Diseases: In Vivo Pharmacology", British Journal of Dermatology, vol. 137, pp. 568-576, 1997.  |             |      |  |
|   | C328        | MENTER, and Barker, "Psoriasis Practice", The Lancet, vol. 338, pp. 231-234, 1991.   |             |      |  |
|   | C329        | Merck Manual, Seventeenth Ed. Pp 303-313, 448, 725-729, 1474-1476  |             |      |  |
|   | C330        | Mesalamine Study Group, "An Oral Preparation of Mesalamine as Long-Term Maintenance Therapy for Ulcerative Colitis: A Randomized Placebo-Controlled Trial", Annals of Internal Medicine, vol. 124, pp. 204-211, 1996.  |             |      |  |
|   | C331        | MEUER et al. (1984) "An Alternative Pathway of T Cell Activation: A Functional Role for the 50 kd TII Sheep Erythrocyte Receptor Protein" Cell 36:897-906.   |             |      |  |
|   | C332        | MEUER et al. (1984) "The human T-cell receptor" Ann. Rev. Immunol. 2:23-50.  |             |      |  |
|   | C333        | MEUER et al. (1989) "The Alternative Pathway of T Cell Activation: Biology, Pathophysiology, and Perspectives for Immunopharmacology" Clin. Immunol. Immunopath. 50:S133-S138.   |             |      |  |
|   | C334        | MICHLER, et al. "Pretransplant blood transfusion in a primate cardiac xenograft model", Curr. Surg. 44(1):42-45 (1987)   |             |      |  |
|   | C335        | MICHLER, et al., "Technique for primate heterotopic cardiac xenotransplantation", J. Med. Primatol. 14:357-362 (1985)  |             |      |  |
|   | C336        | MICHLER, et al., "Prolongation of primate cardiac xenograft survival with cyclosporine", Transplantation 44(5):632-636 (1987)  |             |      |  |
|   | C337        | MIKAYAMA, et al., "Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor", PNAS 90:10056-10060 (1993)   |             |      |  |
|   | C338        | MILLER et al. (1993) "Specific interaction of lymphocyte function associated antigen 3 with CD2 can inhibit T cell responses," J. Exp. Med. 178: 211-222.  |             |      |  |
|   | C339        | MOINGEON et al. (1989) "The Structural Biology of CD2" Immunol. Rev. 111:111-144.  |             |      |  |
|   | C340        | MOINGEON et al. (1989), "CD2-mediated adhesion facilitates T lymphocyte antigen recognition function," Nature 339: 312-339.  |             |      |  |
|   | C341        | MOINGEON et al. (1991) "Complementary Roles For CD2 And LFA-1 Adhesion Pathways During T Cell Activation" Eur. J. Immunol. 21:605-610.   |             |      |  |
|   | C342        | MORDENTI, "Forecasting Cephalosporin and Monobactam Antibiotic Half-Lives in Humans from Data Collected in Laboratory Animals", Antimicrobial Agents and Chemotherapy, vol. 27, No. 6, pp. 887-891, 1985.  |             |      |  |
|   | C343        | MORELAND, et al. "Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis", Arthritis and Rheumatism 36(3) (1993)  |             |      |  |
|   | C344        | MORELAND, et al., "Biological Agents for Treating Rheumatoid Arthritis", Arthritis and Rheumatism, vol. 40, No. 3, pp. 397-409, 1997   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 22 | of | 33 | Attorney Docket Number   | 253780           |


**OTHER - NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|----------------------|-------------|--|-------------|------|
|                      |             |  | Yes         | No** |
|                      | C345        | MORISON, et al., "Consensus Workshop on the Toxic Effects of Long-Term PUVA Therapy" Arch Dermatol, vol. 134, pp. 595-598, 1998.   |             |      |
|                      | C346        | MORONEY, S. E., et al., "Modification of the Binding Site(s) of Lectins by an Affinity Column Carrying an Activated Galactose-Terminated Ligand," Biochemistry, 26, pp. 8390-8398 (1987).  |             |      |
|                      | C347        | MORRISON, S. L., "Transfectomas Provide Novel Chimeric Antibodies," Science, 229, pp. 1202-1207 (Sep. 20, 1985).   |             |      |
|                      | C348        | MOSMANN, et al., "The Expanding Universe of T-Cell Subsets: Th1, Th2 and More", Immunology Today, vol. 17, No. 3, pp. 138-145, 1996.   |             |      |
|                      | C349        | MROWIETZ, et al., "Long-Term Maintenance Therapy with Cyclosporine and Posttreatment Survey in Severe Psoriasis: Results of a Multicenter Study", Journal of the American Academy of Dermatology, vol. 33, No. 3, pp. 470-475, 1995.                             |             |      |
|                      | C350        | MUCHENBERGER, et al., "The Combination of Oral Acitrecin and Bath PUVA for the Treatment of Severe Psoriasis", British Journal of Dermatology, vol. 137, pp. 587-589, 1997.  |             |      |
|                      | C351        | MULLIGAN et al., "Selection for Animal Cells that Express the Escherichia Coli Gene Coding for Xanthine-Guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. U.S.A., 78:2072-2076 (1981).  |             |      |
|                      | C352        | MURRAY, et al., "A 12-Month Treatment of Severe Psoriasis with Acitrecin: Results of a Canadian Open Multicenter Study", Journal of the American Academy of Dermatology, vol. 24, No. 4, pp. 598-602, 1991.  |             |      |
|                      | C353        | MUSSI, et al., "Serum TNF-Alpha Levels Correlate with Disease Severity and are Reduced by Effective Therapy in Plaque-Type Psoriasis", J Biol Regul Homeost Agents, vol. 11, No. 3, pp. 115-118, 1997.   |             |      |
|                      | C354        | NAIR, et al., "Evidence for Two Psoriasis Susceptibility Loci (HLA and 17q) and Two Novel Candidate Regions (16q and 20p) by Genome-Wide Scan", Human Molecular Genetics, vol. 6, No. 8, pp. 1349-1356, 1997.  |             |      |
|                      | C355        | NAKAKURA, et al., "Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion", Transplantation 55(2):412-417 (1993)                                |             |      |
|                      | C356        | NALDI, et al., "Analytical Epidemiology in Psoriasis", Journal of Investigative Dermatology, vol. 102, No. 6, pp. 19S-23S, 1994.   |             |      |
|                      | C357        | NATHAN et al. (1986) "Local and Systemic Effects of Intradermal Recombinant Interferon-gamma in Patients with Lepromatous Leprosy" New Eng. J. Med. 315(1):6-15.   |             |      |
|                      | C358        | NEUBERGER et al., "Recombinant antibodies possessing novel effector functions", 1984, Nature, vol. 312:604-608.  |             |      |
|                      | C359        | NGO et al. "Computational complexity, protein structure prediction, and the Levinthal paradox" in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (Ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, 1994.                     |             |      |
|                      | C360        | NICHOLAS, et al., "CD4 antibody treatment of severe psoriasis", Lancet 338:321 (1991)  |             |      |
|                      | C361        | NICKOLOFF, "The Cytokine Network in Psoriasis", Arch Dermatol, vol. 127, pp. 871-884, 1991.  |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 


|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 23 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C362        | NICKOLOFF, et al., "Accessory Cell Function of Keratinocytes for Superantigens: Dependence on Lymphocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction", The Journal of Immunology, vol. 150, No. 6, pp. 2148-2159, 1993.          |             |      |  |
|   | C363        | NICKOLOFF, et al., "Cytokine Networks: Immunobiology Surfaces", The Journal of NIH Research, vol. 3, pp. 71-74, 1991.  |             |      |  |
|   | C364        | NISHIBU, et al., "Overexpression of Monocyte-Derived Cytokines in Active Psoriasis: A Relation to Coexistent Arthropathy", Journal of Dermatological Science, vol. 21, pp. 63-70, 1999.  |             |      |  |
|   | C365        | NOURI et al. (1990) "Selective and non-selective loss of immunoregulatory molecules (HLA-A,B,C antigens and LFA-3) in transitional cell carcinoma" J. Br. Cancer 62:603-606.   |             |      |  |
|   | C366        | O'GORMAN, et al., "Genetic Polymorphisms associated with clinical improvement of chronic plaque psoriasis after treatment with alefacept", J. Inves. Derm. 124(4): A40 (2005) (Abstract)   |             |      |  |
|   | C367        | OKAYAMA, et al., "High-Efficiency Cloning of Full-Length cDNA", Mol. Cell. Biol., 2(2): 161-170 (1982).  |             |      |  |
|   | C368        | OLIVIERI, et al., "Therapy with Cyclosporine in Psoriatic Arthritis", Seminars in Arthritis and Rheumatism, vol. 27, No. 1, pp. 36-43, 1997.   |             |      |  |
|   | C369        | OSBAND et al. (1990) "Problem in the investigational Study and Clinical Use of Cancer Immunotherapy" Immunology today 11(6): 193-195.  |             |      |  |
|   | C370        | OSBORN et al. (1995), "Amino acid residues required for binding of lymphocyte function-associated antigen 3 (CD58) to its counter-receptor CD2," J. Exp. Med. 181(1): 429-434.   |             |      |  |
|   | C371        | PARK, and Youn, "Factors Influencing Psoriasis: An Analysis Based upon the Extent of Involvement and Clinical Type", The Journal of Dermatology, vol. 25, pp. 97-102, 1998.  |             |      |  |
|   | C372        | PATEL, et al., "Compatibility of Calcipotriene with Other Topical Medications", Journal of the American Academy of Dermatology, vol. 38, No. 6, pp. 1010-1011, 1998.   |             |      |  |
|   | C373        | PAVLI, et al., "Inflammatory Bowel Disease: Germs or Genes?", The Lancet, vol. 347, pp. 1198, 1996.  |             |      |  |
|   | C374        | PEARSON, et al., "Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis", Annals of Internal Medicine, vol. 122, pp. 132-142, 1995.  |             |      |  |
|   | C375        | PECKHAM, et al., "The Treatment of Severe Psoriasis", Arch Dermatol, vol. 123, pp. 1303-1307, 1987.  |             |      |  |
|   | C376        | PENG, et al., "Ligation of CD2 provides a strong helper signal for the production of the type 2 cytokines", Cell. Immunol., 181(1):76-85 (1997)  |             |      |  |
|   | C377        | PEPINO et al. (1989) "Primate Cardiac Allo- and Xenotransplantation: Modulation of the Immune Response with Photochemotherapy" Eur. Surg. Res. 21:105-113.   |             |      |  |
|   | C378        | PEPINSKY et al. (1991), "The increased potency of cross-linked lymphocyte function-associated antigen-3 (LFA-3) multimers is a direct consequence of changes in valency," J. Biol Chem. 266(27): 18244-18249.  |             |      |  |
|   | C379        | PEPINSKY, et al., "Purification and Partial Sequence Analysis of a 37-kDA Protein that Inhibits Phospholipase A.sub.2 Activity from Rat Peritoneal Exudates", J. Bio. Chem., 261(9), 4239-4246 (1986).   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 24 | of | 33 | Attorney Docket Number   | 253780           |


| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C380        | PETERSON (1987) "Monoclonal Antibody And Ligand Binding Sites Of The T Cell Erythrocyte Receptor (CD2)" Nature 329:842-846.  |             |      |  |
|   | C381        | PETERSON, A. S., "Genetic and Biochemical Analysis of CD2, LFA-3 Interaction," In Genetic Analysis of CD2/LFA and CD4/HIV Interactions, Chapter 1, pp. 1-13, Figure 1A (Harvard University, Cambridge, Massachusetts 1988).                                      |             |      |  |
|   | C382        | PETTIT, "Oral Retinoid for Psoriasis: A Report of a Double Blind Study", Acta Derm Venereol Suppl (Stockh). 1979;59(85):133-6.   |             |      |  |
|   | C383        | PETZELBAUER, et al., "Cyclosporin A Suppresses ICAM-1 Expression by Papillary Endothelium in Healing Psoriatic Plaques", The Journal of Investigative Dermatology, vol. 96, No. 3, pp. 362-386, 1991.  |             |      |  |
|   | C384        | PICKER et al. (1990) "A Unique Phenotype of Skin-associated Lymphocytes in Humans" Am. J. Path. 136(5):1053-1068.  |             |      |  |
|   | C385        | PITZALIS, "Skin and joint disease in psoriatic arthritis: What is the link?" Br. J. Rheum. 37(5): 480-483 (1998).  |             |      |  |
|   | C386        | PITZALIS, et al., "Selective Migration of the Human Helper-Inducer Memory T Cell Subset: Confirmation by In Vivo Cellular Studies", European Journal of Immunology, vol. 21, pp. 369-376, 1991.  |             |      |  |
|   | C387        | PLATT, et al. "Transplantation of discordant xenografts: a review of progress", Immunol. Today 11(12):450-456 (1990)   |             |      |  |
|   | C388        | PODOLSKY, "Inflammatory Bowel Disease", The New England Journal of Medicine, vol. 325, No. 13, pp. 928-1014, 1991.   |             |      |  |
|   | C389        | POIKOLAINEN, et al., "Excess Mortality Related to Alcohol and Smoking Among Hospital-Treated Patients with Psoriasis", Arch Dermatol, vol. 135, pp. 1490-1493, 1999.   |             |      |  |
|   | C390        | POIZOT-MARTIN et al. (1991) "Are CD4 antibodies and peptide T new treatments for psoriasis" The Lancet 337:1477  |             |      |  |
|   | C391        | POLITO, et al., "Preliminary Evidence for Genetic Anticipation in Crohn's Disease", The Lancet, vol. 347, pp. 798-800, 1996.   |             |      |  |
|   | C392        | PRENS, et al., "T Lymphocytes in Psoriasis", Clinics in Dermatology, vol. 13, pp. 115-129, 1995.   |             |      |  |
|   | C393        | PRENTICE "Deaths Linked to Growth Hormone" The Times (London), April 6, 1991 (Cited for argument)  |             |      |  |
|   | C394        | PRINCE (1989) "Requirement For Both The CD3/T Cell Receptor Complex And The CD2/Lymphocyte Function-Associated Antigen-3 Adhesion System in Monocyte-Independent T Cell Activation By Oxidized Erythrocytes" Immunol. Investigations 18:1081-1093.               |             |      |  |
|   | C395        | PRINZ et al. (1991) "Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis" The Lancet 338:320-321.   |             |      |  |
|   | C396        | PRINZ, "Which T Cells Cause Psoriasis?", Clinical and Experimental Dermatology, vol. 24, pp. 291-295, 1999.  |             |      |  |
|   | C397        | QIN et al, "Induction of classical transplantation tolerance in the adult", J. Exp. Med. 169(3):779-794 (1989)   |             |      |  |
|   | C398        | QUEEN et al, "A humanized antibody that binds to the interleukin 2 receptor", PNAS 86:10029-10033 (1989)   |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).




Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 25 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |  |             |      |  |
|---|----------|--|-------------|------|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |          |  | Yes         | No** |  |
|   | C399     | RAMAKRISHNAN, S. and L. L. Houston, "Comparison of the Selective Cytotoxic Effects of Immunotoxins Containing Ricin A Chain or Pokeweed Antiviral Protein and Anti-Thy 1.1 Monoclonal Antibodies," Cancer Research, 44, pp. 201-208 (Jan. 1984).                 |             |      |  |
|   | C400     | Rao, et al., "C-Terminal Modification Occurs in Tissue Culture Produced OKT3", Biopharm-The Technology & Business of Biopharmaceuticals, 1991, V4, N10, P38-43.  |             |      |  |
|   | C401     | RAU, et al., "Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy", J. Rheumatol. 25(8):1485-1492 (1998)   |             |      |  |
|   | C402     | RECNY et al. (1990) "Structural And Functional Characterization Of The CD2 Immunoadhesion Domain" J. Biol. Chem. 265(15):8542-8549.  |             |      |  |
|   | C403     | REETSMA, "Xenografts", Transplantation Proceedings 21(1):517-518 (1989)  |             |      |  |
|   | C404     | REFSUM, et al., "Fasting Plasma Homocysteine as a Sensitive Parameter of Antifolate Effect: A Study of Psoriasis Patients Receiving Low-Dose Methotrexate Treatment", Clinical Pharmacology Therapy, vol. 46, No. 5, pp. 510-520, 1989.                          |             |      |  |
|   | C405     | REICHLIN, M., "Use of Glutaraldehyde as a Coupling Agent for Proteins and Peptides," In Methods in Enzymology, 70, edited by Van Vunakis et al., (Academic Press, New York, 1980) pp. 159-165 (1980).  |             |      |  |
|   | C406     | REICHMANN, et al., "Reshaping human antibodies for therapy", Nature 332:323-327 (1998)   |             |      |  |
|   | C407     | REILLY, et al., "Compartmental Analysis of the Pharmacokinetics of Radioiodinated Monoclonal Antibody B72.3 in Colon Cancer Patients", Nucl. Med. Biol, vol. 20, No. 1, pp. 57-64, 1993.   |             |      |  |
|   | C408     | REILLY, et al., "Problems of Delivery of Monoclonal Antibodies; Pharmaceutical and Pharmacokinetic Solutions", Clinical Pharmacokinetics, vol. 28, No. 2, pp. 126-142, 1995.   |             |      |  |
|   | C409     | REIMANN et al.; "In Vivo Administration of Lymphocyte-Specific Monoclonal Antibodies in Nonhuman Primates" (Transplantation--December 1989 pp. 906-912).   |             |      |  |
|   | C410     | RICHARDSON, N.E., et al., "Adhesion Domain of Human T11 (CD2) is Encoded by a Single Exon," Proc. Natl. Acad. Sci. (USA), 85, pp. 5176-5180 (1988).  |             |      |  |
|   | C411     | RIGGS et al. (1996), "The pharmacokinetic/pharmacodynamic (PK/PD) modeling of immunoglobulin fusion protein, LFA3TIP, using a non-linear saturable cell activity model," Pharmaceutical Research 13 (9 Supp.): s398 (Abstract)                                   |             |      |  |
|   | C412     | RINCON and Patarroyo (1989) "Effect Of Antibodies From The T Cell (CD2' Only) And The NK/Non-Lineage (New Panel Only) Sections On Adhesion Of Jurkat (T) Cell to Human Erythrocytes" Tissue Antigens 33:285.   |             |      |  |
|   | C413     | RIVERS, et al., "UVA Sunbeds: Tanning, Photoprotection, Acute Adverse Effects and Immunological Changes", British Journal of Dermatology, vol. 120, pp. 767-777, 1989.   |             |      |  |
|   | C414     | RODRIGUEZ, et al., "Optic Neuritis Posed a 40-Year Risk of 60% for Multiple Sclerosis", ACP Journal Club, vol. 122-123: 21, 1995.  |             |      |  |
|   | C415     | ROITT, Immunology, Gower Medical Pub. (1985) - Immunology textbook   |             |      |  |
|   | C416     | ROSE, "Risks of Cardiac Transplantation", Ann. Thoracic Surg. 47:645 (1989)  |             |      |  |
|   | C417     | ROSE, et al. "Immunosuppression in Cardiac Transplantation", Biblthca Cardiol. 43:1-9 (1988)   |             |      |  |
| Examiner Signature                      |          | Date Considered  |             |      |  |

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |                          |                        |        |
|---|----|----|--------------------------|------------------------|--------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |        |
|   |    |    | Application Number       | 10/588,323             |        |
|   |    |    | Filing Date              | February 7, 2005       |        |
|   |    |    | First Named Inventor     | MAGILAVY               |        |
|   |    |    | Group Art Unit           | 1644                   |        |
|   |    |    | Examiner Name            | Unassigned             |        |
| Sheet   | 26 | of | 33                       | Attorney Docket Number | 253780 |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |
|---|-------------|--|-------------|------|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.                             | Translation |      |
|   |             |  | Yes         | No** |
|   | C418        | ROSE, et al. "Humoral immune responses after cardiac transplantation: Correlation with fatal rejection and graft atherosclerosis", Surgery 106(1):203-208 (1989)   |             |      |
|   | C419        | ROSE, et al., "Cardiac Xenotransplantation", Prog. Cardiovasc. Diseases 33(2):105-117 (1990)   |             |      |
|   | C420        | ROSE, et al., "Present Status of Human Cardiac Allografts and Prospects for Xenografts", Trans Am. Soc. Artif. Intern. Organs 34:19-23 (1988)  |             |      |
|   | C421        | RUDINGER, J. "Characteristics of the amino acids as components of a peptide hormone sequence" in Peptide Hormones, Parson, J. A. (Ed.), University Park Press, Baltimore, MD, pp. 1-7, 1976.   |             |      |
|   | C422        | SACHS, et al., "Immunology of Xenograft Rejection", Hum. Immunol. 28:245-251 (1990)  |             |      |
|   | C423        | SALMI, et al., "Dual Binding Capacity of Mucosal Immunoblasts to Mucosal and Synovial Endothelium in Humans: Dissection of the Molecular Mechanisms", Journal of Experimental Medicine, vol. 181, pp. 137-149, 1995.   |             |      |
|   | C424        | SALMI, et al., "Homing of Mucosal Leukocytes to Joints: Distinct Endothelial Ligands in Synovium Mediate Leukocyte-Subtype Specific Adhesion", Journal of Clinical Investigation, vol. 99, No. 9, pp. 2165-2172, 1997.   |             |      |
|   | C425        | SANCHEZ-MADRID, F. et al., "Three Distinct Antigens Associated with Human T-Lymphocyte-Mediated Cytolysis: LFA-1, LFA-2, and LFA-3," Proc. Natl. Acad. Sci. USA, 79, pp. 7489-7493 (Dec. 1982).  |             |      |
|   | C426        | SANDER, et al., "The Annual Cost of Psoriasis", Journal of the American Academy of Dermatology, vol. 28, No. 3, pp. 422-425, 1993.   |             |      |
|   | C427        | SANDERS et al. (1988) "T Cell Adhesion Receptors LFA-1 And CD2 And Their Ligands ICAM-1 And LFA-3" Analysis in Adhesion, Cell Mediated Lysis, And As Markers Of T Cell Subsets in The T-Cell Receptor, A.R. Liss, Inc., pp. 269-279.   |             |      |
|   | C428        | SANDERS, et al., "Human Memory T Lymphocytes Express Increased Levels of Three Cell Adhesion Molecules (LFA-3, CD2, and LFA-1) and Three Other Molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma. Production", The Journal of Immunology, vol. 140, No. 5, pp. 1401-1407, 1988 |             |      |
|   | C429        | SAVAGE et al. (1991), "Endothelial cell lymphocyte function-associated antigen-3 and an unidentified ligand act in concert to provide costimulation to human peripheral blood CD4.sup.+ T cells," Cellular Immunology 137(1): 150-163.   |             |      |
|   | C430        | SAYRE et al. (1987), "Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes" Chemical Abstracts 107(15): Abstract 128218x.   |             |      |
|   | C431        | SAYRE, et al. "Molecular cloning and expression of T11 cDNAs reveal a receptor-like structure on human T lymphocytes", PNAS 84:2941-2945 (1987)  |             |      |
|   | C432        | SCHNEIDER, et al., (Abstract) "A pilot study of the safety and efficacy of Alefacept in subject with active rheumatoid arthritis on methotrexate" European League Against Rheumatism (2003)  |             |      |
|   | C433        | SCHOPF (1986) "Stimulation of T Cells by Autologous Molecular Leukocytes and Epidermal Cells in Psoriasis" Arch. Dermatol. Res. 279:89-94.   |             |      |
|   | C434        | SCHOPF, "Interactions between epidermal cells and lymphocytes in psoriasis", Immunology Today 7:358 (1988)   |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →




|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 27 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |   |             |     |  |
|---|----------|---|-------------|-----|--|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.                          | Translation |     |  |
|   |          |   | Yes         | No* |  |
|   | C435     | SCHRAVEN, et al., "Alternations of CD2 Association with T Cell Receptor Signaling Molecules in 'CD2 Unresponsive' Human T Lymphocytes", European Journal of Immunology, vol. 23, pp. 119-123, 1993.   |             |     |  |
|   | C436     | SCHWARTZ, et al., "Identification of the TS2/18-Recognized Epitope on the CD2 Molecule as a Target for Suppression of T Cell Cytokine Synthesis", The Journal of Immunology, vol. 154, pp. 5813-5820, 1995.   |             |     |  |
|   | C437     | SCHWEIGHOFFER, et al. "Adhesions cascades: diversity through combinatorial strategies", Curr. Opin. Cell. Biol. 4(5):824-829 (1991)   |             |     |  |
|   | C438     | SEED, et al. (1987) "Molecular Cloning of the CD2 Antigen, The T-Cell Erythrocyte Receptor, By A Rapid immunoselection procedure" Proc. Natl. Acad. Sci. USA 84:3365-3369.  |             |     |  |
|   | C439     | SEED, B. "An LFA-3 cDNA Encodes a Phospholipid-Linked Membrane Protein Homologous to its Receptor CD2," Nature, 329, pp. 840-842 (1987).  |             |     |  |
|   | C440     | SEED, et al., "Molecular Cloning of the CD2 Antigen, the T-Cell Erythrocyte Receptor, By a Rapid Immunoselection Procedure," Proc. Natl. Acad. Sci. USA, 84, pp. 3365-3369 (May 1987).  |             |     |  |
|   | C441     | SELVARAJ et al. "Deficiency of Lymphocyte Function Associated Antigen 3 (LFA3) in Paroxysmal Nocturnal Hemoglobinuria," J. Exp. Med., 166, pp. 1011-1025 (1987).  |             |     |  |
|   | C442     | SELVARAJ et al. (1987) "The T Lymphocyte Glycoprotein CD2 (LFA-2/T11/E-Rosette Receptor) Binds The Cell Surface Ligand LFA-3" FASEB J. 46(3):447 Abstract 760.  |             |     |  |
|   | C443     | SELVARAJ, P. et al., "The T Lymphocyte Glycoprotein CD2 Binds the Cell Surface Ligand LFA-3," Nature, 326, pp. 400-403 (Mar. 1987).   |             |     |  |
|   | C444     | SEMNANI et al. (1994), "Costimulation by purified intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 induces distinct proliferation, cytokine and cell surface antigen profiles in human "naive" and "memory" CD4.sup.+ T cells," J. Exp. Med. 180:2125-2135. |             |     |  |
|   | C445     | SEO, "Evaluation of Disease Activity in Patients with Moderately Active Ulcerative Colitis: Comparisons Between a New Activity Index and Truelove and Witts' Classification", The American Journal Of Gastroenterology, vol. 90, No. 10, pp. 1759-1763, 1995.                             |             |     |  |
|   | C446     | SEWELL et al. (1986) "Molecular Cloning Of The Human T-Lymphocyte Surface CD2 (T11) Antigen" Proc. Natl. Acad. Sci. USA 83:8718-8722.   |             |     |  |
|   | C447     | SHAHIDULLAH, et al., "Etretnate Therapy for Psoriasis and Other Keratinizing Disorders: A 10-Year Retrospective Study in Singapore", International Journal of Dermatology, vol. 32, No. 9, pp. 686-689, 1993.   |             |     |  |
|   | C448     | SHANAHAN, "Pathogenesis of Ulcerative Colitis", The Lancet, vol. 342, pp. 407-411, 1993.  |             |     |  |
|   | C449     | SHAW et al. (1986) "Two Antigen-Independent Adhesion Pathways Used By Human Cytotoxic T-Cell Clones" Nature 323:262-264.  |             |     |  |
|   | C450     | SHAW, et al., "Cyclosporin A and Vitamin D Metabolism: Studies in Patients with Psoriasis and in Rats", Clinical Science, vol. 86, pp. 627-632, 1994.   |             |     |  |
|   | C451     | SHAW, S. and G. E. Ginther Luce, "The Lymphocyte Function-Associated Antigen (LFA)-1 and CD2/LFA-3 Pathways of Antigen-Independent Human T Cell Adhesion," J. Immunol., 139, pp. 1037-1045 (Aug. 15, 1987).   |             |     |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 


|   |            |    |    |                          |                  |
|---|------------|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |            |    |    | <b>Complete if Known</b> |                  |
|   |            |    |    | Application Number       | 10/588,323       |
|   |            |    |    | Filing Date              | February 7, 2005 |
|   |            |    |    | First Named Inventor     | MAGILAVY         |
|   |            |    |    | Group Art Unit           | 1644             |
| Examiner Name   | Unassigned |    |    |                          |                  |
| Attorney Docket Number  | 253780     |    |    |                          |                  |
| Sheet   | 28         | of | 33 |                          |                  |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C452        | SHIMIZU, et al "Four Molecular Pathways of T Cell Adhesion to Endothelial Cells: roles of :FA-1, VCAM-1 and ELAM-1 and Changes in Pathway Hierarchy Under Different Activation Conditions", J. Cell. Biol. 113(5):1203-1212 (1991)                               |             |      |  |
|   | C453        | SHORT, J. M., et al., ".lambda. ZAP: A Bacteriophage Expression Vector with In Vivo Excision Properties," Nucleic Acids Research, 16(15), pp. 7583-7600 (1988).  |             |      |  |
|   | C454        | SHUPAK, "Maintenance Therapy with Neoral.RTM.", International Journal of Dermatology, vol. 36, pp. 34-36, 1997.  |             |      |  |
|   | C455        | SIMON et al. (1991) "Adhesion molecules CD11a, CD18, and ICAM-2 on Human Epidermal Langerhans Cells Serve a Functional Role in the Activation of Alloreactive T Cells" Soc. Invest. Dermat. 96(1): 148-151.  |             |      |  |
|   | C456        | SINGER et al. (1990) "Thymocyte LFA-1 And Thymic Epithelial Cell ICAM-1 Molecules Mediate Binding Of Activated Human Thymocytes To Thymic Epithelial Cells" J. Immunol. 144(8):2931-2939.  |             |      |  |
|   | C457        | SINGER, K.H. et al. "The Role of Adhesion Molecules in Epithelial - T-Cell Interactions in Thymus and Skin", J. Invest. Dermatol. 94 (6) Supplement: 85S-90S.  |             |      |  |
|   | C458        | SINGH, et al., "Acute Immobilization Stress Triggers Skin Last Cell Degranulation via Corticotropin Releasing Hormone, Neurotensin, and Substance P: A Link to Neurogenic Skin Disorders", Brain Behavior, and Immunity, vol. 13, pp. 225-239, 1999.             |             |      |  |
|   | C459        | SMITH, et al. (1990) "Cellular Expression Of Lymphocyte Function Associated Antigens And The Intercellular Adhesion Molecule-1 In Normal Tissue" J. Clin. Path. 43 (11):893-900.   |             |      |  |
|   | C460        | SMITH, and Barker, "Cell Trafficking and Role of Adhesion Molecules in Psoriasis", Clinics in Dermatology, vol. 13, pp. 151-160, 1995.   |             |      |  |
|   | C461        | SOFER and Britton "Designing an Optimal Chromatographic Purification Scheme for Proteins" Bio/Techniques 1(4):198-203 (1983)   |             |      |  |
|   | C462        | SOMERVILLE, and Scott, "Neoral-New Cyclosporin For Old?", British Journal of Rheumatology, vol. 36, pp. 1113-1115, 1997.   |             |      |  |
|   | C463        | SOUTHERN, E. M. "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", J. Mol. Biol., 98, 503-517 (1975).   |             |      |  |
|   | C464        | SPADARO, et al., "Comparison of cyclosporine A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study", Clin. Exp. Rheum. 13:589-593 (1995)  |             |      |  |
|   | C465        | SPRINGER "Adhesion Receptors Of The Immune System" Nature 346:425-434.   |             |      |  |
|   | C466        | SPRINGER (1987) "The Lymphocyte Function-Associated LFA-1, CD2, And LFA-3 Molecules: Cell Adhesion Receptors Of The Immune System" Ann. Rev. Immunol. 5:223-252.   |             |      |  |
|   | C467        | SPULS et al., "A Systematic Review of Five Systematic Treatments for Severe Psoriasis", British Journal of Dermatology, vol. 137, pp. 943-949, 1997.   |             |      |  |
|   | C468        | SRINIVASACHAR, K. and D. M. Neville, Jr., "New Protein Cross-Linked Reagents That Are Cleaved by Mild Acid," Biochemistry, 28(4), pp. 2501-2509 (1989).  |             |      |  |
|   | C469        | STAUNTON et al. (1989) "Molecular characterization of ICAM-1 and ICAM-2; Alternate Ligands for LFA-1" Tissue Antigens 33:287 (Abstract)  |             |      |  |
|   | C470        | Stedman's Medical Dictionary, (1976) The Williams & Wilkins Company, Baltimore, MD, p. 810.  |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 


|   |    |    |                          |                        |        |
|---|----|----|--------------------------|------------------------|--------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |        |
|   |    |    | Application Number       | 10/588,323             |        |
|   |    |    | Filing Date              | February 7, 2005       |        |
|   |    |    | First Named Inventor     | MAGILAVY               |        |
|   |    |    | Group Art Unit           | 1644                   |        |
|   |    |    | Examiner Name            | Unassigned             |        |
| Sheet   | 29 | of | 33                       | Attorney Docket Number | 253780 |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |
|---|-------------|--|-------------|------|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|   |             |  | Yes         | No** |
|   | C471        | STERN, "Narrowband UV-B and Psoriasis", Arch Dermatol, vol. 133, pp. 1587-1588, 1997.  |             |      |
|   | C472        | STERN, "Psoriasis", The Lancet, vol. 350, pp. 349-353, 1997.   |             |      |
|   | C473        | STERN, "Utilization of Outpatient Care for Psoriasis", Journal of the American Academy of Dermatology, vol. 35, No. 4, pp. 543-549, 1996.  |             |      |
|   | C474        | STERN, et al., "Malignant Melanoma in Patients Treated for Psoriasis with Methoxsalen (Psoralen) and Ultraviolet A Radiation (PUVA)", The New England Journal of Medicine, vol. 336, No. 15, pp. 1041-1045, 1997.  |             |      |
|   | C475        | STERN, et al., "The Safety of Etretinate as Long-Term Therapy for Psoriasis: Results of the Etretinate Follow-Up Study", Journal of the American Academy of Dermatology, vol. 33, No. 1, pp. 44-52, 1995.  |             |      |
|   | C476        | STORKUS, and Dawson, "A Target Structures Involved in Natural Killing (NK): Characteristics, Distribution, and Candidate Molecules", Immunology, vol. 10, No. 5, 393-416, 1991.  |             |      |
|   | C477        | STRAND, "The Future Use of Biologic Therapies in Combination for the Treatment of Rheumatoid Arthritis", J. Rheumatol. 23 (suppl. 44):91-96 (1996)   |             |      |
|   | C478        | SULTAN, et al., "Blockade of CD2-LFA-3 Interactions Protects Human Skin Allografts in Immunodeficient Mouse/Human Chimeras", Nature Biotechnology, vol. 15, pp. 759-762, 1997.   |             |      |
|   | C479        | SURANJI et al. (1991) "Lymphocyte Adhesion Molecules in T Cell-Mediated Lysis of Human Kidney Cells" Kidney International 39:312-319.  |             |      |
|   | C480        | SUTHERLAND, et al., "Standards for Trials of Therapy in Inflammatory Bowel Disease", Inflammatory Bowel Diseases, vol. 3, No. 4, pp. 277-283, 1997.  |             |      |
|   | C481        | TADINI (1989) "Adhesion Molecules Expression in Psoriasis" J. Invest. Dermatol. 93(2):309A (Abstract).   |             |      |
|   | C482        | TALWAR, et al., "Sequential Clinico-Histological Studies in Psoriasis Following Methotrexate Therapy", Ind J Dermatol Venereol Leprol, vol. 61, pp. 284-287, 1995.   |             |      |
|   | C483        | TAND and Udey (1991) "Inhibition of Epidermal Langerhans Cell Function by Low Dose of Ultraviolet B Radiation" J. Immunol. 146(10):3347-3355.  |             |      |
|   | C484        | Task Force of the Working Group on Arrhythmias of the European Society of Cardiology, "The Early Termination of Clinical Trials: Causes, Consequences, and Control", European Heart Journal, vol. 15, pp. 721-738, 1994.   |             |      |
|   | C485        | The Merck Manual of Diagnosis and Therapy Sixteenth Edition Edited by Berkow et al., Merck Research Laboratories, Rahway NJ 1992, pp. 2435-2445.*  |             |      |
|   | C486        | THOMAS, et al., "Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis", The New England Journal of Medicine, vol. 332, No. 15, pp. 988-992, 1995.  |             |      |
|   | C487        | THOMAS, et al., "Purification of Membrane Proteins" in Methods in Enzymology, Deutscher, M. ed., (Academic Press, San Diego) 182: 499 (1990) (cited for argument)  |             |      |
|   | C488        | TICHO, et al., "Reduced T cell monitoring in psoriasis patients receiving alefacept: results of clinical studies and mathematical modeling", J. Inves. Derm. 124(4): A40 (2005) (Abstract)   |             |      |
|   | C489        | TRAUNECKER et al., "A novel approach for preparing anti-T cell receptor constant region antibodies", 1986, Eur. J. Immunol., vol. 16:851-854.  |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 


|   |    |    |                          |                        |        |
|---|----|----|--------------------------|------------------------|--------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |        |
|   |    |    | Application Number       | 10/588,323             |        |
|   |    |    | Filing Date              | February 7, 2005       |        |
|   |    |    | First Named Inventor     | MAGILAVY               |        |
|   |    |    | Group Art Unit           | 1644                   |        |
|   |    |    | Examiner Name            | Unassigned             |        |
| Sheet   | 30 | of | 33                       | Attorney Docket Number | 253780 |

| OTHER - NON PATENT LITERATURE DOCUMENTS |          |  |             |      |
|---|----------|--|-------------|------|
| Examiner Initials                       | Doc. No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|   |          |  | Yes         | No** |
|   | C490     | TRAUNECKER et al., "Soluble CD4 molecules neutralize human immunodeficiency virus type 1", 1988, Nature, vol. 331:84-86.   |             |      |
|   | C491     | TRAUPE, "The Puzzling Genetics of Psoriasis", Clinics in Dermatology, vol. 13, pp. 99-103, 1995.   |             |      |
|   | C492     | TREMBATH, et al., "Identification of a Major Susceptibility Locus on Chromosome 6p and Evidence for Further Disease Loci Revealed by a Two Stage Genome-Wide Search in Psoriasis", Human Molecular Genetics, vol. 6, No. 5, pp. 813-820, 1997.                   |             |      |
|   | C493     | UCHIO, et al., "Suppression of Experimental Uveitis With Monoclonal Antibodies to ICAM-1 and LFA-1", Invest. Ophthalmol. Vis. Sci. 35(5):2626-2631 (1994)  |             |      |
|   | C494     | ULLMAN et al. (1990) "Transmission of Signals from T Lymphocyte Antigen Receptor to the Genes Responsible for Cell Proliferation and Immune Function: The Missing Link" Ann. Rev. Immunol. 8:421-452.  |             |      |
|   | C495     | URLAUB, and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity", Proc Natl Acad Sci, vol. 77, No. 7, pp. 4216-4220, 1980.  |             |      |
|   | C496     | URLAUB, et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions", Somatic Cell and Molecular Genetics, vol. 12, No. 6, pp. 555-566, 1986.   |             |      |
|   | C497     | VALDIMARSSON et al. (1986) "Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes" Immunol. Today 7:256-259.  |             |      |
|   | C498     | VALDIMARSSON, et al., "Psoriasis: A T-Cell-Mediated Autoimmune Disease Induced by Streptococcal Superantigens?", Immunology Today, vol. 16, No. 3, pp. 145-149, 1995.  |             |      |
|   | C499     | VAN DE KERKHOF, "An Update on Vitamin D3 Analogues in the Treatment of Psoriasis", Skin Pharmacology and Applied Skin Physiology, vol. 11, pp. 2-10, 1998.   |             |      |
|   | C500     | VAN DE KERKHOF, "Reduction of Epidermal Abnormalities and Inflammatory Changes in Psoriatic Plaques During Treatment with Vitamin D3 Analogs", Journal of Investigative Dermatology Symposium Proceedings, vol. 1, pp. 78-81, 1996.                              |             |      |
|   | C501     | VAN DE KERKHOF, "Review: The Management of Psoriasis", Netherlands Journal of Medicine, vol. 52, pp. 40-45, 1998.  |             |      |
|   | C502     | VAN DE KERKHOF, "The Psoriasis Area and Severity Index and Alternative Approaches for the Assessment of Severity: Persisting Areas of Confusion", British Journal of Dermatology, vol. 137, pp. 661-662, 1997.   |             |      |
|   | C503     | VAND DE KERKHOF, et al., "Evaluation of Topical Drug Treatment in Psoriasis", Dermatology, vol. 197, pp. 31-36, 1998.  |             |      |
|   | C504     | VAN DE KERKHOF, et al., "TheEffect of Addition of Calcipotriol Ointment (50 .mu.g/g) to Acitretin Therapy in Psoriasis", British Journal of Dermatology, vol. 138, pp. 84-89, 1998.  |             |      |
|   | C505     | VAN DER MERVE, et al., "Human Cell-Adhesion Molecule CD2 Binds CD58 (LFA-3) with a Very Low Affinity and an Extremely Fast Dissociation Rate but does not Bind CD48 or CD59", Biochemistry, vol. 33, pp. 10149-10160, 1994.                                      |             |      |
|   | C506     | VAN DER RHEE, et al., "Combined Treatment of Psoriasis with a New Aromatic Retinoid (Tigason) in Low Dosage Orally and Triamcinolone Acetonide Cream Topically: A Double-Blind Trial", British Journal of Dermatology, vol. 102, pp. 203-211, 1980.              |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 


|   |            |    |                          |                  |  |
|---|------------|----|--------------------------|------------------|--|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |            |    | <b>Complete if Known</b> |                  |  |
|   |            |    | Application Number       | 10/588,323       |  |
|   |            |    | Filing Date              | February 7, 2005 |  |
|   |            |    | First Named Inventor     | MAGILAVY         |  |
|   |            |    | Group Art Unit           | 1644             |  |
| Examiner Name   | Unassigned |    |                          |                  |  |
| Attorney Docket Number  | 253780     |    |                          |                  |  |
| Sheet   | 31         | of | 33                       |                  |  |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |
|---|-------------|--|-------------|------|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |
|   |             |  | Yes         | No** |
|   | C507        | VAN KOOYK, et al., "Enhancement of LFA-1-Mediated Cell Adhesion by Triggering through CD2 or CD3 on T Lymphocytes", Nature, vol. 342, pp. 811-813, 1989.   |             |      |
|   | C508        | VAN NORT, et al., "Cell Biology of Autoimmune Diseases", in International Review of Cytology: A Survey of Cell Biology, Jeon, K. ed. (Academic Press, San Diego, 1998), pp127-207  |             |      |
|   | C509        | VAN ONSELEN, "Psoriasis in General Practice", Nursing Standard, vol. 12, No. 30, pp. 32-33, 1998.  |             |      |
|   | C510        | VAN SEVENTER et al. (1989) "The Three LFA-3 Specific Monoclonal Antibodies in the Non-Lineage panel of Workshop Monoclonal Antibodies All Inhibit T-Cell Rosetting" Tissue Antigens 33:298 (Abstract).   |             |      |
|   | C511        | VAN SEVENTER, et al. "Roles of multiple accessory molecules in T-cell activation", Curr. Opin. Immunol. 3(3):294-303 (1991)  |             |      |
|   | C512        | VERHOEVEN, et al., "Combination Therapy in Rheumatoid Arthritis: Updated systematic review", Br. J. Rheum. 37:612-619(1998)  |             |      |
|   | C513        | VERSTUYF, et al., "Recent Developments in the Use of Vitamin D Analogues", Expert Opin Investig Drugs, vol. 9, No. 3, pp. 397-403, 1998.   |             |      |
|   | C514        | VIRELLA et al. (1988) "The Interaction of CD2 With Its LFA-3 Ligand Expressed By Autologous Erythrocytes Results in Enhancement of B Cell Responses" Cell. Immunol. 116:308-319.   |             |      |
|   | C515        | VOLLGER et al. (1987) "Thymocyte Binding To Human Tymic Epithelial Cells is Inhibited By Monoclonal Antibodies To CD-2 And LFA-3 Antigens" J. Immunol. 138(2):358-363.   |             |      |
|   | C516        | WAHL, "The Impact of Psoriasis on Psychosocial Life Domains: A Review", Scandinavian Journal of Caring Science, vol. 11, pp. 243-249, 1997.  |             |      |
|   | C517        | WAHL, et al., "Sulfasalazine: A Potent and Specific Inhibitor of Nuclear Factor Kappa B", Journal of Clinical Investigation, vol. 101, No. 5, pp. 1163-1174, 1998.   |             |      |
|   | C518        | WALDMAN (1991) "Monoclonal Antibodies in Diagnosis and Therapy" Science 252:1657-1662.   |             |      |
|   | C519        | WALLNER et al (1987) "Primary Structure of Lymphocyte Function-Associated Antigen 3 (LFA-3)--The Ligand of the Lymphocyte CD2 Glycoprotein" J. Exp. Med. 166(4):923-931.   |             |      |
|   | C520        | WALLNER, et al., "Cloning and Expression of Human Lipocortin, a Phospholipase A2 Inhibitor with Potential Anti-Inflammatory Activity", Nature, 320(6), 77-81 (1986).   |             |      |
|   | C521        | WALTERS, et al., "Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris", J.Acad. Dermatol. 40(6) 893-900   |             |      |
|   | C522        | WANG, et al., "Structure of a Heterophilic Adhesion Complex between the Human CD2 and CD58 (LFA-3) Counterreceptors", Cell, vol. 97, pp. 971-803, 1999.  |             |      |
|   | C523        | WANG, X. et al., "A Vector That Expresses Secreted Proteins on the Cell Surface," DNA, 8(10), pp. 753-758 (Dec. 1989).   |             |      |
|   | C524        | WANQUINQ, et al., "Clinical Study of Cyclosporin A for Psoriasis in China", Annals of Dermatology, vol. 7, No. 4, pp. 313-317, 1995.   |             |      |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

|   |    |    |    |                          |                  |
|---|----|----|----|--------------------------|------------------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |    |    | <b>Complete if Known</b> |                  |
|   |    |    |    | Application Number       | 10/588,323       |
|   |    |    |    | Filing Date              | February 7, 2005 |
|   |    |    |    | First Named Inventor     | MAGILAVY         |
|   |    |    |    | Group Art Unit           | 1644             |
|   |    |    |    | Examiner Name            | Unassigned       |
| Sheet   | 32 | of | 33 | Attorney Docket Number   | 253780           |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C525        | WATANABE, et al., "Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques", Nature 337:267(1989) (cited for argument)   |             |      |  |
|   | C526        | WEBB et al. (1990) "LFA-3, CD44, And CD45: Physiologic Triggers Of Human Monocyte TNF And IL-1 Release" Science 249:1295-1297.   |             |      |  |
|   | C527        | WEINBLATT, "Efficacy of Methotrexate in Rheumatoid Arthritis" Br. J. Rheum. 34(S2)43-48 (1995)   |             |      |  |
|   | C528        | WEINBLATT, et al., "Methotrexate for Chronic Diseases in Adults", The New England Journal of Medicine, vol. 332, No. 5, pp. 330-331, 1995.   |             |      |  |
|   | C529        | WEINBLATT, et al., "Efficacy of Methotrexate in Rheumatoid Arthritis", Br. J. Rheum. 34(Supp 2):43-48 (1995)   |             |      |  |
|   | C530        | WEINER, et al., "Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin A Chain Immunoconjugate", Cancer Research, vol. 49, pp. 4062-4067, 1989.   |             |      |  |
|   | C531        | WEINSTEIN, "Psoriasis Therapy After Remission: The Next Step", International Journal of Dermatology, vol. 36(Suppl 1), pp. 37-40, 1997.  |             |      |  |
|   | C532        | WEINSTEIN, "Tazarotene Gel: Efficacy and Safety in Plaque Psoriasis", Journal of the American Academy of Dermatology, vol. 37, No. 2, pp. S33-S38, 1997.   |             |      |  |
|   | C533        | WEINSTEIN, et al., "Tazarotene Gel, a New Retinoid, for Topical Therapy of Psoriasis: Vehicle-Controlled Study of Safety, Efficacy, and Duration of Therapeutic Effect", Journal of the American Academy of Dermatology, vol. 37, No. 1, pp. 85-92, 1997.        |             |      |  |
|   | C534        | WEISS, and Ashwell, "The Asialoglycoprotein Receptor: Properties and Modulation by Ligand", Baumann, P., et al. (ED.). Progress in Clinical and Biological Research, vol. 300.   |             |      |  |
|   | C535        | WENDLING, et al. "Therapeutic Use of Monoclonal Anti-CD4 Antibody in Rheumatoid Arthritis", J. Rheum. 18(3): 325-7 (1991) ) (abstract only)  |             |      |  |
|   | C536        | WEYAND, et al. "Immunosuppression by Anti-CD4 Treatments In Vivo", Transplantation 47(6):1039-1042 (1989)  |             |      |  |
|   | C537        | WHITCUP, et al., "Monoclonal Antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) Inhibit Experimental Autoimmune Uveitis", Clin. Immunol Immunopathol 67(2):143-150 (1993)   |             |      |  |
|   | C538        | WHITMORE, and Morison, "Melanoma after PUVA Therapy for Psoriasis", The New England Journal of Medicine, vol. 337, No. 7, pp. 502, 1997.   |             |      |  |
|   | C539        | WILLKENS, et al., "Randomized, Double-Blind, Placebo Controlled Trial of Low-Dose Pulse Methotrexate in Psoriatic Arthritis", Arthritis and Rheumatism, vol. 27, No. 4, pp. 376-381, 1984.   |             |      |  |
|   | C540        | WINTER and Harris (1993) "Humanized antibodies" TIPS 14(5):139-142.  |             |      |  |
|   | C541        | WOLSKA, et al., "Etretinate in Severe Psoriasis: Results of Double-Blind Study and Maintenance Therapy in Pustular Psoriasis", Journal of the American Academy of Dermatology, vol. 9, No. 6, pp. 883-887, 1983.   |             |      |  |
|   | C542        | WONG et al., "Identification of a Partial cDNA Clone for the Human Receptor for Complement Fragments C3b/C4b," Proc. Natl. Acad. Sci. U.S.A., 82, 7711-7715 (1985).  |             |      |  |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



Please type a plus sign (+) inside this box → +

|   |    |                      |    |                          |  |        |
|---|----|----------------------|----|--------------------------|--|--------|
| Substitute for form 1449A/B/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |    |                      |    | <b>Complete if Known</b> |  |        |
|   |    | Application Number   |    | 10/588,323               |  |        |
|   |    | Filing Date          |    | February 7, 2005         |  |        |
|   |    | First Named Inventor |    | MAGILAVY                 |  |        |
|   |    | Group Art Unit       |    | 1644                     |  |        |
|   |    | Examiner Name        |    | Unassigned               |  |        |
| Sheet   | 33 | of                   | 33 | Attorney Docket Number   |  | 253780 |

| OTHER - NON PATENT LITERATURE DOCUMENTS |             |  |             |      |  |
|---|-------------|--|-------------|------|--|
| Examiner<br>Initials                    | Doc.<br>No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published. | Translation |      |  |
|   |             |  | Yes         | No** |  |
|   | C543        | WONG, et al., "Mechanisms of action of cyclosporine A in the treatment of psoriasis", Immunol. Today 14(2):69-74 (1993).   |             |      |  |
|   | C544        | WOOD, W. I. (1987) "Gene Cloning Based on Long Oligoneucleotide Probes", Meth. Entymol. 152:443-47.  |             |      |  |
|   | C545        | WRIGHT, et al., "Human Low-Dosage Parenteral Methotrexate Therapy: A Controlled Toxicity Study", Arch Derm, vol. 93, pp. 731-736, 1966.  |             |      |  |
|   | C546        | Written Opinion PCT/US02/02314   |             |      |  |
|   | C547        | YAMASHITA, et al., "A multimeric form of soluble recombinant sheep LFA-3 (CD-58) inhibits human T-cell proliferation" Immunol. 92(1):39-44 (1997)  |             |      |  |
|   | C548        | YEH, et al., "Recombinant Soluble Human Complement Receptor Type 1 Inhibits Inflammation in the Reversed Passive Arthus Reaction in Rats", J. Immunol. 146(1):250 (1991) (cited for argument   |             |      |  |
|   | C549        | YOCUM, et al., "Clinical and immunological effects of a Primatized Anti-CD4 Monoclonal Antibody in Active Rheumatoid Arthritis: Results of a Phase I, Single Dose, Dose Escalating Trial", Journal of Rheumatology, vol. 25, pp. 1257-1262, 1998.                |             |      |  |
|   | C550        | YONG and Khwaja (1990) "Leukocyte Cellular Adhesion Molecules" Blood Reviews 4(4):211-225.   |             |      |  |
|   | C551        | YOUNG, et al., "A Prospective study of Renal Structure and Function in Psoriasis Patients with Cyclosporin", Kidney International, vol. 46, pp. 1216-1222, 1994.   |             |      |  |
|   | C552        | ZACHARIAE, "Alcohol Interaction with Drugs and its Effects on the Treatment of Skin Diseases", Clinics in Dermatology, vol. 17, pp. 443-445, 1999.   |             |      |  |
|   | C553        | ZETTLMEISSL, et al., "Expression and Characterization of Human CD4: Immunoglobulin Fusion Proteins", DNA & Cell Biol. 9(5):347-353 (1990)  |             |      |  |
|   | C554        | ZHENG et al. (1990) "Expression Of Intercellular Adhesion Molecule-1 And Lymphocyte Function-Associated Antigen-3 On Human Thyroid Epithelial Cells In Graves' And Hashimoto's Diseases" J. Autoimmunity 3:727-736.  |             |      |  |
|   | C555        | Translation of Examiner's report for Czech Patent Application No. PV 2001-725  |             |      |  |

|                    |                 |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).